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Abstract
Obesity is the unhealthy accumulation of adipose tissue and affects 10% of the global
population. A study reported the loss of mouse pannexin 1 (Panx1), a large channel forming
protein, increased adipogenesis in murine adipose derived stem cells (ASCs). Our study
was designed to determine if human pannexin 1 (PANX1) inhibits adipogenesis in vitro
using human ASCs and induced-mesenchymal stem cells (iMSCs) derived from induced
pluripotent stem cells (iPSCs). Pharmacological inhibition of PANX1 using carbenoxolone
halted adipogenesis in both the ASCs and iMSCs. When PANX1 was inhibited by
probenecid, adipogenesis was impeded in iMSCs, but not in ASCs. PANX1-ablated iPSCs
were able to differentiate into iMSCs and further differentiate along the adipogenic lineage.
Our findings indicate that PANX1 expression is not essential for iPSC differentiation to
iMSCs, nor adipogenesis, and the contrasting responses of iMSCs and ASCs to probenecid
suggests that mesenchymal stem cells from different origins have distinct characteristics.
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Lay Summary
Approximately 10% of the global population is obese according to the World Health
Organization. Obesity is the unhealthy increase of fat tissue, or adipose tissue, and is linked
to comorbidities such as cardiovascular disease and type 2 diabetes. Dietary lipids are
stored in adipose tissue within cells called adipocytes. During periods of overeating,
adipocytes accommodate the additional lipids by increasing in either size or number.
Larger adipocyte size leads to mechanical stress and contributes to obesity-related
consequences. It has been speculated that by promoting adipocyte production, or
adipogenesis, the extra lipids could be distributed among more cells, limiting the need to
increase cell size and thus possibly avoiding obesity related disorders.
Adipocytes originate from mesenchymal stem cells (MSCs), a cell type capable of
becoming cartilage, bone, or fat cells. MSCs can be collected from various sources,
including adipose tissue and induced pluripotent stem cells (iPSCs). During adipogenesis,
specific genes are expressed to initiate the MSCs’ transformation into functional adipocytes
that can store lipids. The loss of pannexin 1 (Panx1) was reported to increase adipogenesis
in mouse adipose derived mesenchymal stem cells (ASCs). Pannexin 1 are channel forming
proteins that allow molecules to pass through the cell’s membrane. Although human ASCs
express PANX1, it is unclear whether PANX1 influences human adipogenesis.
In our study, human ASCs and iPSC-derived MSCs (iMSCs) were cultured in adipogenic
conditions to promote adipogenesis, as indicated by lipid droplet formation. To study
PANX1 channel function, cells undergoing adipogenesis were untreated, or treated with
either carbenoxolone (CBX) or probenecid (Prob), which are both drugs that block PANX1
channels. CBX inhibited adipogenesis in both the ASCs and iMSCs; however, Prob
impeded adipogenesis in only the iMSCs, and not the ASCs. Furthermore, PANX1 was
genetically removed from iPSCs, and these cells were able to transition into iMSCs and
further undergo adipogenesis in vitro. Overall, we conclude that PANX1 is not required
for human adipogenesis in vitro, and the contrasting responses from ASCs and iMSCs to
Prob implies that MSCs from different sources have distinct characteristics. These findings
suggest that PANX1 may not be an ideal target to regulate human adipogenesis in vitro.
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Chapter 1

1

Introduction

1.1

Adipose Tissue

Adipose tissue is the largest endocrine organ in the body, and serves multiple functions
such as storing energy, maintaining metabolic hemostasis, healing wounds, and regulating
inflammation (Cohen & Spiegelman, 2016). Adipose tissue consists of a variety of cells,
but the predominant ones are adipocytes (Desruisseaux et al., 2007). Adipocyte levels in
the body can range from 5% of the body mass in athletes to 60% of body mass in obese
individuals (Fleck, 1983; Ortega et al., 2009). Adipocytes can also be divided into two
tissue types: brown adipose tissue (BAT) and white adipose tissue (WAT) (Fitzgerald et
al., 2018). BAT adipocytes are between 15 μm to 50 μm with an ovoid shape and are filled
with mitochondria, giving the cells their brown colored appearance (Fitzgerald et al.,
2018). BAT is prominently found in infants, and has a high mitochondrial density which
is key for thermoregulation through lipid oxidation (Choe et al., 2016). As the infant grows,
the BAT is replaced with WAT, the primary focus of our study (Choe et al., 2016). A
majority of WAT is located within two depots: visceral fat (VAT; within the abdominal
cavity) and subcutaneous fat (SAT; beneath the skin) (Ghaben & Scherer, 2019). WAT
adipocytes have a spherical shape and a diameter that can range from 10 μm to 120 μm,
and is primarily responsible for insulation and energy storage (Choe et al., 2016). They
possess a single large unilocular lipid droplet that pushes the nucleus and other organelles
towards the periphery (Fitzgerald et al., 2018). The accumulation of lipids, which is
responsible for the white color of WAT, serve an important function as energy reserves for
the body (Fitzgerald et al., 2018).
1.1.1

Functions of Adipocytes

During postprandial periods, WAT adipocytes use a process called lipogenesis to convert
excess energy (in the form of glycerol and free fatty acids (FFA)) into triglycerides (TG),
which are stored in lipid droplets for future use (Cohen & Spiegelman, 2016). Upon fasting,
adipocytes hydrolyze the stored TG back to glycerol and FFA via lipolysis, which is then
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released into the circulation for delivery to other tissue (Frayn et al., 2006; Cohen &
Spiegelman, 2016). The functions of both fat storage and release of FFA are controlled by
hormones in the fed and fasted state (Cohen & Spiegelman, 2016). Insulin is the main
regulator of adipocyte fat content, and enhances FFA uptake and TG synthesis in
adipocytes (Cohen & Spiegelman, 2016). Adipocytes also serve an endocrine function
through the production and secretion of several cytokines, also known as adipokines
(Halberg et al., 2008). These cytokines include adiponectin (an insulin sensitizing
hormone), tumor necrosis factor alpha (TNFα; a proinflammatory signal), and leptin
(nutritional intake regulator) (Coelho et al., 2013). Adipocytes therefore maintain the
physiological functions of many organs and tissues, including the liver, pancreas, skeletal
muscles, kidneys, endothelium, and the immune system (Halberg et al., 2008; Coelho et
al., 2013). Other functions of adipocytes include insulating the body, cushioning parts of
the body exposed to high levels of mechanical stress (e.g. the heels of the hands and feet),
as well as protect delicate organs from damage (e.g. orbital fat cushions the eyes and
supports the extraocular muscles to perform eye movements) (Rosen & Spiegelman, 2014;
Wester, 2014). Adipocytes are also important to facilitate wound healing, where adipocytes
can direct fibroblasts to heal acute burns and chronic non-healing ulcers (Schmidt &
Horsley, 2013; Ghaben & Scherer, 2019).
1.1.2

Dysregulated Adipocytes

Dysregulated adipose tissue has been linked to adipose-related diseases such as obesity,
type 2 diabetes, and lipodystrophy (Garg, 2006). Obesity is a chronic and complex disease
marked by changes in adipocyte secretory function and chronic low-grade inflammation
(Hajer et al., 2008). The unhealthy increase in adipose tissue in obese patients has been
shown to increase the risk of comorbidities, such as cardiovascular disease, type 2 diabetes,
and cancer (Tao & Lagergren, 2013; Hruby & Hu, 2015). Despite these consequences,
there has been an increase in obesity rates, with one in three Canadians being overweight
or obese (Hruby & Hu, 2015). Obesity is determined by a patient’s body mass index (BMI),
calculated as weight (in kilograms) over height (in meters), where a BMI over 25 is
regarded as overweight and a BMI over 30 is considered obese (Gesta et al., 2007). In
obese patients, adipocytes must adjust to accommodate the excess dietary lipids by either
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undergoing hypertrophy (increase in cell size) or hyperplasia via adipogenesis (increase in
cell number) (Ghaben & Scherer, 2019). During the early stages of obesity, adipocytes
address the increase in lipids by undergoing both hypertrophy and hyperplasia (Gesta et
al., 2007). In the later stages however, adipocytes often undergo hypertrophy primarily,
and the larger cells have been shown to endure more mechanical stress as well as face
hypoxia due to their size (Gesta et al., 2007; Ghaben & Scherer, 2019). This results in
lower insulin sensitivity and a steady decline in metabolic health (Ghaben & Scherer,
2019). Enlarged adipocytes release more FFA, where the excess FFA can bind to
macrophages and initiate the release of TNFα, a pro-inflammatory signal (Choe et al.,
2016; Engin, 2017). The release of TNFα reduces adipocyte insulin sensitivity by inhibiting
genes for insulin signaling and adipocyte differentiation (Cawthorn et al., 2007; Coelho et
al., 2013). It has been proposed that increasing hyperplasia via adipogenesis would
decrease the size of adipocytes, and therefore reduce the risks of negative health
consequences (Ghaben & Scherer, 2019).
As mentioned, type 2 diabetes is a health consequence of obesity. Over 2 million people in
Canada have type 2 diabetes, a disease where the production or response to insulin is
impaired (www150.statcan.gc.ca; Yang et al., 2012). Diabetic complications include
neuropathy, nephropathy, retinopathy, cardiovascular disease, stroke, impaired wound
healing, and peripheral artery disease, all contributing to the significant mortality of type 2
diabetic patients (Papatheodorou et al., 2018; Ghaben & Scherer, 2019). A recent study
showed that 61% of the women with types 2 diabetes were overweight or obese (Hajer et
al., 2008). Another study reported that patients with type 2 diabetes possessed enlarged,
insulin resistant adipocytes when compared to non-diabetic patients (Yang et al., 2012). It
is believed that, like obesity, increasing adipogenesis can help to reduce adipocyte cell size
and alleviate the symptoms of diabetes (Ghaben & Scherer, 2019).
Paradoxically, individuals that lack adipose tissue share similar symptoms as those that
have an excess (Garg, 2006). Lipodystrophy is a pathological state of adipose deficiency,
resulting in abnormal energy storage and irregular adipokine production (Garg, 2006). Due
to the lack of adipose tissue, excess lipids accumulate in other areas, such as the liver,
muscles, pancreas, and kidneys, causing lipid toxicity, or lipotoxicity (Castro et al., 2014).
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These ectopic fat deposits can result in non-alcoholic fatty liver disease, as well as hepatic
insulin resistance and skeletal muscle insulin resistance which both eventually lead to the
development of type 2 diabetes (Garg, 2006; Hafner & Dani, 2014). By promoting
adipocyte production in lipodystrophic patients we can alleviate the negative symptoms
related to this disease.
Understanding the production and maintenance of adipocytes is important, since
dysregulation of adipocytes can result in severe metabolic disorders. By studying factors
that influence adipocyte production, we can identify targets to help regulate it for treating
these adipose-related diseases. For instance, increasing adipogenesis in obese patients can
help maintain smaller adipocyte sizes and reduce the hypoxic effects which can lead to
obesity-related health consequences. Similarly, lipodystrophic patients who lack
adipocytes can benefit from promoting adipogenesis, so that lipids can be properly stored
in adipocytes rather than causing lipotoxicity by accumulating in other tissues. In this
study, we investigate the production of human adipocytes and how it is regulated, in hopes
that our findings can further the understanding of adipogenesis and contribute to the
treatment of adipose-related diseases.
1.1.3

Adipogenesis

Adipogenesis, the process of adipocyte production, must be carefully regulated to maintain
an equilibrium between sustaining energy homeostasis and avoiding the risks for obesitylinked diseases. This differentiation process occurs frequently to compensate for cell death,
with approximately 10% of adipocytes being renewed annually (Spalding et al., 2008).
Adipocytes originate from mesenchymal stem cells (MSCs) which undergo adipogenesis
through a cascade of transcription factors, mostly centered around peroxisome proliferatoractivated receptor gamma (PPARγ) and CCAAT enhancer binding protein alpha (CEBPα)
(Lowe et al., 2011). The process can be divided into two steps: the commitment step (MSC
to preadipocyte) and the differentiation step (preadipocyte to mature adipocyte) (Ghaben
& Scherer, 2019). During the commitment step, MSCs become restricted to the adipogenic
lineage, and thus are no longer able to pursue other fates such as the osteogenic and
chondrogenic lineages (Farmer, 2006; Cristancho & Lazar, 2011; Cawthorn et al., 2012a).
Currently, there are no reliable markers to distinguish MSCs from pre-adipocytes (Gesta
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et al., 2007). The differentiation step can be further broken down into four stages: growth
arrest, early differentiation (mitotic clonal expansion), intermediate differentiation (postmitotic growth arrest), and terminal differentiation (Figure 1.1) (Gregoire et al., 1998;
Chang & Kim, 2019). Growth arrest is required for adipogenesis, where proadipogenic
transcription factors PPARγ and CEBPα inhibit the Wnt signaling pathway to exit the cell
cycle (Umek et al., 1991; Altiok et al., 1997; Gregoire et al., 1998; Lowe et al., 2011). The
growth arrested preadipocytes synchronically re-enter the cell cycle (referred to as mitotic
clonal expansion), where CEBPα binds to DNA to initiate the transcription of adipogenic
factors (Umek et al., 1991; Tang et al., 2003), a vital step for adipogenesis. Intermediate
differentiation is orchestrated by interactions between PPARγ and CEBPα, where both of
these transcription factors induce the transcription of mature adipogenic genes, such as
adiponectin, as well as the formation of lipid droplets (Wu et al., 1999; Lefterova et al.,
2008). Terminal differentiation is indicated by the presence of a unilocular lipid droplet,
the activity of adipogenic proteins such as glycerol-3-phosphate dehydrogenase (GPDH;
participates in lipid biosynthesis and glycerol production), and the secretion of adiponectin
(ADIPOQ; hormone that regulates energy substrates and body composition) (Park et al.,
2009; Meyer et al., 2013). It is quite apparent from the differentiation process that PPARγ
is the master regulator of adipogenesis (Lowe et al., 2011). PPARγ has two isoforms, of
which PPARγ2 is most notable in adipogenesis (Gesta et al., 2007). PPARγ facilitates
adipogenesis with the help of the CEBP proteins, especially CEBPα, where 90% of PPARγ
DNA binding sites also bind to CEBPα (Ghaben & Scherer, 2019). Together, PPARγ and
CEBPα bind to DNA to initiate the expression of adipogenic proteins such as lipoprotein
lipase (LPL), ADIPOQ, perilipin and GPDH (Lowe et al., 2011).
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Figure 1.1 Stages of Adipocyte Differentiation
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Figure 1.1: Stages of Adipocyte Differentiation. A schematic of the differentiation steps
where preadipocytes differentiate into mature adipocytes. This step can be divided into
four stages: growth arrest, early differentiation (mitotic clonal expansion), intermediate
differentiation (post-mitotic growth arrest), and terminal differentiation. aP2 (adipocyte
fatty-acid-binding protein 2); CEBP (CCAAT enhancer binding protein); FAS (fatty-acid
synthase); LPL (lipoprotein lipase); PPAR (peroxisome proliferator-activated receptor);
Pref-1 (preadipocyte factor-1). Modified figure used with permission from Chang E & Kim
C (2019). Natural Products and Obesity: A Focus on the Regulation of Mitotic Clonal
Expansion during Adipogenesis. Molecules 24, 1157.
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In two dimensional (2D) in vitro cultures, MSCs are cultured in adipogenic media to induce
adipogenesis, and develop multilocular lipid droplets indicative of immature adipocytes
(Klingelhutz et al., 2018). In our study, we used a previously published adipogenic media
for adipose derived stem cells (ASCs) (Flynn, 2010). Each ingredient of this specialized
media has been specifically selected to promote adipogenesis. Biotin, also known as
vitamin B, increases the rate of FFA incorporation into TG by promoting acetyl
carboxylase, which is the first step for long-chain FFA synthesis (Levert et al., 2002).
Pantothenate, or vitamin B5, is required to synthesize coenzyme A, which is a key
component in FFA synthesis (Wang et al., 2013; Huber & Kluger, 2015). Transferrin is a
key iron-binding protein, which stimulates a lipolytic effect through the presence of iron
(Rumberger et al., 2004). Hydrocortisone is a glucocorticoid that promotes differentiation
by increasing levels of CEBPα and insulin sensitivity, as well as facilitating growth arrest
required for terminal differentiation. Insulin stimulates the uptake of amino acids and
glucose into the cell, and also initiates cell signaling involved in adipogenesis (Hauner et
al., 1987; Gerhold et al., 2002; Garofalo et al., 2003; Hynes et al., 2014). Triiodothyronine
(T3) interacts with two primary thyroid receptor (TR) isoforms, TRa1 and its antagonist
TRa2, within adipose tissue (Ortega et al., 2010). T3 interacts with TRa1 to induce
adipogenesis, while Tra2 inhibits T3 activity (Ortega et al., 2010). 3-isobutyl-1methylxanthine (IBMX) regulates adipogenesis as a competitive non-selective
phosphodiesterase inhibitor, and raises the levels of cAMP and protein kinase A, which
signal for the transcriptional activity of PPARγ (Kim et al., 2010). Finally, troglitazone is
a PPARγ2 agonist and acts as an insulin sensitizer to enhance adipogenesis (Gerhold et al.,
2002; Kim et al., 2010).
1.1.4

Factors Affecting Adipogenesis

Donor age, sex, and BMI have been reported to influence the adipogenic potential of
MSCs. For example, in one study, ASCs from the patients over the age of 70 were able to
undergo adipogenesis more efficiently, as indicated by a significant increase in PPARγ
mRNA levels, adiponectin secretion, and lipid droplet formation (Kornicka et al., 2015).
However, another study investigated the effects of age on adipogenesis by calculating the
percentage of ASCs that were positive for oil red O (Zhu et al., 2009). This study found
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that there was no correlation between age and adipogenesis, and therefore the influence of
age on adipogenesis remains debatable (Zhu et al., 2009). Another reported factor in
adipogenesis is high BMIs. A study showed that BMI was negatively correlated with the
number of ASCs per gram of adipose tissue, as well as the ASCs’ capacity to perform
adipogenesis (van Harmelen et al., 2003). This may be due to obese patients having a
smaller pool of cells capable of adipogenesis compared to healthy patients (van Harmelen
et al., 2003). Finally, sex differences have also been reported to affect adipogenesis. A
study showed that the Pparγ2 mRNA levels of ASCs harvested from female mice is 2.9
times greater than those harvested from male mice (Ogawa et al., 2004). In the human
context, larger SAT is typically found in women when compared to men (Björntorp, 1991).
This suggests that the adipogenic differentiation of ASCs is closely related to sex
differences.
1.1.5

Adipose Tissue in Mice and Humans

Much of what we know about adipogenesis is based on experiments using mouse models;
but there are several obvious and subtle differences in adipose tissue physiology between
these species that must be considered. BMI is a highly inheritable characteristic, where
genetics is responsible for up to 70% of the variability in humans (Chusyd et al., 2016).
Mice strains used in obesity experiments are commonly inbred, so theoretically they are
genetically similar (Chusyd et al., 2016). Hence the findings from a single strain may not
reflect the genetically polymorphic human population. In adipose tissue specifically, there
are anatomical and cellular differences between humans and mice. Adipocytes constitute
only a third of adipose tissue in animals, while in humans about 50% of the adipose tissue
is composed of adipocytes (Ali et al., 2013). The remaining adipose tissue consists of small
blood vessels, nerve tissue, fibroblasts and preadipocytes (Ali et al., 2013). Humans also
have two main SAT depots, in the abdominal and gluteofemoral regions, whereas rodents
have two main subcutaneous pads, located anteriorly and posteriorly (Chusyd et al., 2016).
Humans have two layers of SAT separated by superficial fascia; however, there is no
evidence of multiple subcutaneous layers in rodents (Chusyd et al., 2016). Furthermore,
rodent SAT is separated from dermal adipose tissue by a smooth muscle layer, whereas in
humans the SAT is continuous with adipose tissue (Chusyd et al., 2016). These anatomical
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variations in adipose tissue between species are likely due to the differential gene
expression profiles of Tbox transcription factor 15 (transcription factor for craniofacial and
limb development), secreted frizzled related protein 2 (modulator of Wnt signaling), and
glypican 4 (involved in cell division and growth), between the adipose depots of both
species (Gesta et al., 2006). At the cellular level, human and murine adipocytes have
different protein expression and function. Catecholamine-induced lipolysis is required for
the breakdown of stored TG into FFA and glycerol, and is mostly driven by activation of
three beta adrenergic receptor (β-AR) subtypes (β1, β2, and β3) (Chusyd et al., 2016).
Humans and mice both express β1-AR and β2-AR; however, β3-AR is ubiquitously found
in mouse adipose tissue, while being marginally expressed in human adipocytes (Chusyd
et al., 2016). Therefore, β3-AR agonists are able to induce lipolysis in murine adipocytes,
but are unable to produce the same effect in human adipocytes in vitro or in vivo (Tavemier
et al., 1996; Weyer et al., 1998). On the other hand, human adipocytes express α2adrenergic receptors, which is absent in murine adipocytes (Chusyd et al., 2016). α2receptors have a higher affinity to catecholamines, and, when activated, inhibit lipolysis
(Langin, 2006). This indicates that catecholamines may have a different role in lipolysis
depending on the species. Also, natriuretic peptides induce lipolysis through the c-GMP
pathway, independent of the catecholamine-β-AR pathway (Sengenès et al., 2002). This
phenomenon appears to be primate specific, as it is not observed in rodents (Sengenès et
al., 2002). Finally, LIM domain only 3 (LMO3) is believed to play a role in human
adipogenesis by responding to the presence of glucocorticoids (a vital component of
adipogenic media) (Lindroos et al., 2013). However, LMO3 is not found in mice,
indicating that they may be some differences in adipogenic induction between mice and
humans (Lindroos et al., 2013). Due to these differences, conclusions based on mouse
models should be validated in the human context to determine if the findings apply to
humans.
1.2

Mesenchymal Stem Cells

To study adipogenesis, we need to understand the adipocyte precursor, MSCs. In general,
stem cells are defined by two unique characteristics: they are capable of self-renewal, and
can differentiate to other cell types in adult organisms (De Wert & Mummery, 2003). As
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stem cells differentiate into another cell type, the gene expression profile changes and
specific gene markers are up regulated or down regulated (Zhao et al., 2012). MSCs are a
class of stem cells that can differentiate into a limited number of cell types, including
adipocytes, chondrocytes, fibroblasts, and osteoblasts (Strioga et al., 2012). MSCs serve a
role in growth, immunosuppression, and tissue repair (Shao et al., 2015). Due to these
characteristics, there is a clinical interest in MSCs as a cellular therapy to treat many
conditions, including tissue injuries or degenerative diseases (Wei et al., 2013). In some
clinical trials, MSCs have been isolated, differentiated in vitro, and implanted into patients
to repair tissues (Ohgushi et al., 2005; Wei et al., 2013). It is therefore important to gain a
clear understanding of MSCs during in vitro differentiation, to determine their potential for
clinical use in humans.
According to the International Society for Cellular Therapy, there are three criteria to
define MSCs. First, the MSCs must be capable of adhering to plastic (Dominici et al.,
2006). MSCs are required to have ≥95% expression of CD73 (ecto-5’-nuclotidase), CD90
(Thy-1), and CD105 (endoglin), and have ≤2% expression of CD34 (hematopoietic
progenitor antigen) and CD45 (leukocyte common antigen) (Dominici et al., 2006). Lastly,
MSCs must be able to differentiate into adipocytes, chondrocytes, and osteoblasts
(Dominici et al., 2006). Adipocytes differentiated from MSCs have been reported to
express adipocyte markers such as PPARγ, ADIPOQ, LPL, and GPDH (Gimble et al.,
2008; Yu et al., 2017; Mohamed-Ahmed et al., 2018). These adipocytes form intracellular
lipid droplets which can be detected using oil red O, as well as express functional GPDH
used to synthesize glycogen (Sheyn et al., 2016; Yu et al., 2017). Based on these criteria
and previous studies, cells can be identified as MSCs and their differentiation into
adipocytes can be studied in detail.
MSCs were first isolated from the bone marrow, but since then, MSCs have be harvested
from a variety of tissues, including adipose tissue, peripheral blood, placenta, and umbilical
cord blood (Wei et al., 2013). Interestingly, tissue origin appears to influence the
differentiation ability of the MSCs. MSCs have an enhanced ability to differentiate into the
tissue they were isolated from (Gimble et al., 2008; Mohamed-Ahmed et al., 2018). For
example, bone marrow derived MSCs (BM-MSCs) have earlier and higher levels of
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osteoblast markers compared to adipose-derived stem cells (ASCs), while on the other hand
ASCs expressed higher transcript levels of adipocyte markers and greater lipid droplet
formation compared to BM-MSCs (Mohamed-Ahmed et al., 2018). Therefore, ASCs’
enhanced ability to differentiate into adipocytes make them an ideal model to study
adipogenesis.
1.2.1

Adipose Derived Stem Cells

ASCs are MSCs isolated from adipose tissue. Within adipose tissue, there is a small
population of cells referred to as the stromal vascular fraction (SVF) (Lowe et al., 2011).
The SVF is composed of endothelial cells, fibroblasts, smooth muscle cells, hematopoietic
cells, and, of course, ASCs (Lowe et al., 2011). In terms of immunophenotype, ASCs are
90% identical to BM-MSCs, with a minor difference in CD34 expression (Strioga et al.,
2012). ASCs express CD34 when freshly isolated, a phenomena which decreases over time,
while all MSCs isolated from other sources do not express CD34 at all (Strioga et al.,
2012). In terms of culture, ASCs demonstrate lower senescence and higher proliferation
capacities over a longer period of time compared to BM-MSCs (Frese et al., 2016).
However, a study reported a significantly lower growth rate for ASCs isolated from
patients over the age of 70 when compared to other age groups (Kornicka et al., 2015).
Overall, ASCs have shown strong regenerative properties through cell restoration and antiinflammation (Frese et al., 2016). Due to their adipogenic potential, ASCs are ideal for
enhancing skin wound repair by improving re-epithelialization, reducing scar formation,
and increasing blood density (Hassan et al., 2014).
With the increasing use of MSCs in clinical trials, it has become apparent that isogenic
MSCs are ideal to avoid immunological rejection. Ideally, MSCs can be isolated from the
patient’s adipose tissue and reintroduced to tissue injury sites to facilitate repair. Compared
to bone marrow, adipose tissue is a preferable source of MSCs due to the ease and low
risks associated with liposuction surgeries, with approximately 1.4 million liposuctions
being performed globally per year (Gimble et al., 2007; Schlarb, 2018). Furthermore,
adipose tissue has a higher yield of MSCs per gram (5%) compared to bone marrow (0.0010.01%) (Strioga et al., 2012). Taking all these factors into consideration, ASCs have
become an ideal candidate for clinical applications of MSCs. To date, there are 270 active
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clinical trials investigating the use of ASCs to treat disorders, including soft tissue
regeneration, skeletal tissue repair, microbial infections, and immune disorders
(www.clinicaltrials.gov; Frese et al., 2016).
1.2.2

Induced Pluripotent Stem Cell Derived Mesenchymal Stem Cells

Regardless of tissue origin, MSCs have a finite self-renewal capacity, and will eventually
give rise to daughter cells that have lost their differentiation potential; severely limiting the
propagation of MSCs (Wagner et al., 2008). To address this, induced pluripotent stem cells
(iPSCs) have become an alternate source of MSCs (Hynes et al., 2016). iPSCs are somatic
cells that have been genetically reprogrammed through the expression of the pluripotent
factors (octamer-binding transcription factor 4, sex determining region Y-box 2, cellular
Myelocytomatosis, and Kruppel like factor 4), and can be propagated indefinitely
(Takahashi et al., 2007). iPSCs are considered primed pluripotent cells, meaning they can
differentiate into any cell type in the body except the placenta, but are more inclined to
differentiate toward a specific lineage due to growth factors (Kilens et al., 2018). By
changing the cellular environment, iPSCs can be both reverted to a naïve-like state, in
which they are less primed to follow a specific cell-fate, and reconverted back to their
primed state, by returning the cells to their original environment (Kilens et al., 2018). The
iPSCs can also be readily differentiated into MSCs, creating an essentially unlimited source
of MSCs (Lian et al., 2010; Sheyn et al., 2016). Furthermore, MSCs derived from iPSCs
have been shown to be capable of adipocyte differentiation as revealed via oil red O
staining (Lian et al., 2010; Sheyn et al., 2016).
1.3

Pannexin 1

Pannexins are a family of channel forming glycoproteins discovered in the year 2000, and
are characterized by their four transmembrane domains which have two extracellular loops
and one intracellular loop, with the N-terminus and C-terminus facing the cytoplasm
(Panchina et al., 2000; Penuela et al., 2013). There are three members in the pannexin
family: pannexin 1, pannexin 2, and pannexin 3 (Penuela et al., 2013). Pannexin 1 (~45
kDa) is ubiquitously expressed throughout the human body, pannexin 2 (~73 kDa) is
predominantly found in the brain, and pannexin 3 (~48 kDa) is primarily expressed in the
bone, cartilage, and skin (Baranova et al., 2004; Penuela et al., 2014). Of all the pannexins,
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pannexin 1 has been the most extensively studied. The pannexin 1 gene is located on
chromosome 11, and consists of five exons (Baranova et al., 2004). At least two isoforms
have been identified, with alternative splicing of the fifth exon, resulting in differences in
the C terminal; however, no functional or trafficking differences have been documented
between the isoforms (Baranova et al., 2004; Penuela et al., 2014).
Pannexins were first discovered due to their sequence homology to the invertebrate gap
junction proteins, innexins, and were named after the Latin words pan (meaning all) and
nexus (meaning connection) (Panchina et al., 2000). While innexins are commonly found
paired as gap junctions between cells, pannexins are usually found functioning as a single
membrane channel. Despite their similar topology, there is no homology between
pannexins and the vertebrate gap junction proteins connexins (Cxs) (Penuela et al., 2013).
It is also notable that, compared to Cxs, pannexin 1 has a much longer half-life (Penuela et
al., 2007). In a study where cells were treated with brefeldin A (BFA), an inhibitor of
protein secretion, pannexin 1 clearance was only noticed after 32 hours of BFA treatment
(Penuela et al., 2007). On the other hand, it took only 3 to 6 hours to observe clearance of
Cx43 (Penuela et al., 2007). These differences show that, while pannexins and Cxs are
both channel forming proteins expressed in vertebrates, their distinct homologies should
be considered when analyzing their biological properties.
Once translated, pannexin 1 proteins must undergo glycosylation for proper trafficking to
the cell membrane. Studies using site-directed mutagenesis revealed that N-glycosylation
occurs in pannexin 1 at N254 (Boassa et al., 2007). There are three glycosylated species of
pannexin 1: the non-glycosylated species (Gly 0), high mannose species (Gly 1) and the
complex glycosylated species (Gly 2) (Penuela et al., 2013). The Gly 0 and Gly 1 species
are predominantly found at the endoplasmic reticulum, while the Gly 2 species is
predominantly found at the plasma membrane surface (Penuela et al., 2009). Furthermore,
the non-glycosylated pannexin 1 proteins have similar channel function as their
glycosylated counterpart, suggesting that glycosylation is required for the proper
trafficking of the pannexin 1 to the plasma membrane (Penuela et al., 2009).
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1.3.1

Pannexin 1 Function

Six pannexin 1 proteins oligomerize into a channel that allows the passage of small
signaling molecules, up to 1 kDa in size, such as ATP and Ca++ (Figure 1.2) (Vanden
Abeele et al., 2006; Penuela et al., 2013). Studies have shown that pannexin 1 channels
can be opened via mechanical stimulation, intracellular calcium, extracellular potassium,
ATP, membrane depolarization, or caspase cleavage (Locovei et al., 2006; Chekeni et al.,
2010). Structural evidence indicates that the outer pore is composed of the first
transmembrane domain and the first extracellular loop, while the C-terminus is believed to
act as a plug to reversibly close the channel (Chekeni et al., 2010; Penuela et al., 2014).
Permanent cleavage of the C-terminus by caspase 3 or 7 will cause the channel to be
irreversibly opened (Chekeni et al., 2010). This feature has been shown to play a key role
in releasing "find me" signals required for apoptotic cell clearance (Chekeni et al., 2010).
pannexin 1 also participates in paracrine signaling as an ATP release channel, facilitating
serotonin release in presynaptic cells during tasting and calcium signaling in hippocampal
pyramidal neurons during epilepsy (Thompson et al., 2008; Vandenbeuch et al., 2015).
Pannexin 1 has also been suggested to form endoplasmic reticulum Ca++ permeable
channels in the human prostate adenocarcinoma cell line (LNCaP), which may play a role
in intracellular signaling (Vanden Abeele et al., 2006).
Pannexin 1 can be pharmacologically inhibited with carbenoxolone and probenecid
(Silverman et al., 2009). Carbenoxolone is an approved treatment for gastroesophageal
reflux disease, and has been shown to have an inhibiting effect on pannexins at lower
concentrations (<100 μM), as well as other channel forming proteins, such as connexins,
at higher concentration (>200 μM) (Pinder et al., 1976; Silverman et al., 2009). Probenecid
is a common gout remedy that inhibits organic anion transporters (Silverman et al., 2008).
Moreover, previous studies have demonstrated that 1 mM probenecid inhibits human
pannexin 1 (PANX1) channel function in Xenopus laevis oocytes that over express
PANX1, and this same concentration has been used to inhibit PANX1 channel function
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Figure 1.2 Diagram of Pannexin 1 Channel Gating
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Figure 1.2: Diagram of Pannexin 1 Channel Gating. Pannexin 1 molecules oligomerized to

form a single membrane channel that allows the passage of molecule smaller than 1 kDa
(A). The glycosylation required for the proper trafficking of the protein is coloured in red,
while the actin which interact with pannexin 1 proteins is shown in yellow. The C-terminus
can block the pore reversibly (B, C) or irreversibly open the channel (D). Figure used with
permission from Penuela S, Harland L, Simek J & Laird DW (2014). Pannexin channels
and their links to human disease. Biochem J 461, 371–381.
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during human skeletal myoblast differentiation (Silverman et al., 2008; Langlois et al.,
2014). Since both small molecules are lipophilic, they can cross the cell membrane and
inhibit pannexin 1 channel function regardless of where pannexin 1 is located (Masereeuw
et al., 2000; Benfenati et al., 2009). As a result, these drugs are frequently used to study
pannexin 1 function in a variety of cell types (Silverman et al., 2009; Langlois et al., 2014;
Bhaskaracharya et al., 2014).
In additional to its channel function, pannexin 1 interacts with other binding partners to
facilitate cell signaling. One of these proteins is actin, which interacts with the C terminus
of pannexin 1 to facilitate proper trafficking and stability in the membrane (Bhalla-Gehi et
al., 2010). Pannexin 1 also interacts with the purinergic channels, P2X and P2Y, to
facilitate cellular activation, apoptosis, and stress signals (Velasquez & Eugenin, 2014).
α1D-adrenergic receptors for phenylephrine are also binding partners of pannexin 1, and
together induce vasoconstriction of resistant arteries (Penuela et al., 2014). Finally,
pannexin 1 participates in the inflammasome complex, along with P2X7 and caspase 1,
within neurons and astrocytes (Silverman et al., 2009). Given this information, it is
important to consider the interaction between pannexin 1 and other proteins when studying
pannexin 1 function.
1.3.2

Pannexin 1 during Cellular Differentiation

Pannexin 1 has been reported to influence differentiation within rat epidermal keratinocytes
(REKs), human skeletal muscle myoblasts (HSMM), and murine ASCs (Celetti et al.,
2010; Langlois et al., 2014; Lee et al., 2018). To study pannexin 1 in keratinocyte
differentiation, murine pannexin 1 (Panx1) was overexpressed in REKs (Panx1-REKs),
which was confirmed by increased dye uptake (Celetti et al., 2010). Using a liquid air
chamber, these Panx1-REKs were differentiated into an organotypic epidermis, comprised
of a 2-3 cell vital layer covered by a cornified layer (Celetti et al., 2010). Cytokeratin 14
(CK14), which is a marker for undifferentiated basal keratinocytes, had increased
expression throughout the Panx1-REK organotypic epidermis compared to the nondifferentiated Panx1-REKs (Celetti et al., 2010). Furthermore, the organotypic epidermis
of the Panx1-REKs had a disorganized epidermal structure, which included a reduction in
vital layer thickness (Celetti et al., 2010). Overall, this study concluded that overexpression
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of Panx1 dysregulated keratinocyte differentiation, indicating that pannexin 1 may play a
role in regulating epidermis renewal (Celetti et al., 2010).
On the other hand, overexpression of PANX1 promoted earlier HSMM differentiation
toward skeletal myotubules, as indicated by the expression of terminal differentiation
markers, myosin heavy chain marker, and the formation of multi-nucleated myotubules
(Langlois et al., 2014). Pharmacological inhibition of PANX1 channel function using
carbenoxolone and probenecid impeded differentiation (Langlois et al., 2014). From these
findings, PANX1 is speculated to release ATP, which is required during HSMM
differentiation (Langlois et al., 2014). In terms of adipogenesis, the loss of Panx1 was
shown to increase murine adipogenesis in ASCs, which will be discussed later in greater
detail (Lee et al., 2018). Based on these studies, it is believed that pannexin 1 is involved
in differentiation, though its role appears to vary depending on the cell types involved and
the state of cell differentiation being assessed.
1.4

Pannexin 1 in Adipocytes

PANX1 is ubiquitous throughout the human body, so it was hardly surprising that PANX1
is expressed in adipose tissue, and specifically in ASCs (Baranova et al., 2004).
Furthermore, PANX1 expression was reported to be positively correlated with insulin
resistance in obese patients, indicating that PANX1 may influence adipocyte function
(Adamson et al., 2015). However, the role of PANX1 in adipocytes remains poorly
understood. Currently, PANX1 is believed to play a role in glucose metabolism in
adipocytes, but the mechanism remains unclear (Adamson et al., 2015). Moreover, there
are limited studies addressing the role of PANX1 in regulating adipogenesis and adiposerelated diseases.
1.4.1

Pannexin 1 in Adipose Related Diseases

Since its discovery, PANX1 has been linked to multiple human diseases, and therefore it
was no shock to find PANX1 related to obesity (Penuela et al., 2014; Adamson et al., 2015;
Lee et al., 2018). Obesity is the accumulation of excess adipose tissue that leads to impaired
adipocyte function, and is characterized as a chronic low-grade inflammation (Hajer et al.,
2008; Castro et al., 2014). In adipocytes, PANX1 was reported to activate inflammasomes
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and increase the release of interleukin 1 beta, a pro-inflammatory cytokine, which in obese
patients may contribute to the obesity-related inflammation (Silverman et al., 2009).
Furthermore, adipose tissue secretes adiponectin, which acts as an anti-inflammatory signal
by inhibiting PANX1 channels (Li et al., 2018). However, during obesity, adipose tissue
has a reduction in adiponectin secretion, resulting in inflammation (Li et al., 2018). In
addition, obesity contributes to the development of insulin resistance and type 2 diabetes
(Castro et al., 2014; Hruby & Hu, 2015). It has been reported that the level of PANX1
expression in adipose tissue of obese patients positively correlates with the degree of
insulin resistance (Adamson et al., 2015). A study using adipose-specific Panx1-knockout
mice reported that Panx1 channels are activated by insulin, and are necessary for glucose
uptake in adipocytes (Adamson et al., 2015). It appears that pannexin 1 is regulated by
insulin, but the mechanism remains uncertain. Overall, the ongoing trend indicates that a
reduction in PANX1 is advantageous in preventing disease onset or progression (Penuela
et al., 2014).
1.4.2

Pannexin 1 in Mice

Through the use of Panx1 knockout mice, an understanding of the key roles for Panx1 in
in vivo and in vitro have greatly advanced. Panx1 is expressed in murine WAT, and when
wild type mice were placed on a high fat diet (HFD; 60% by kcal) there was an increase in
Panx1 in epidermal WAT (Pillon et al., 2014). To further study Panx1, global Panx1knockout (Panx1-KO) mice have been generated (Anselmi et al., 2008; Chekeni et al.,
2010; Seminario-Vidal et al., 2011; Santiago et al., 2011). On a normal diet, Panx1-KO
mice had significantly greater total fat mass and lower lean fat mass (total body weight
minus the weight due to the fat mass) when compared to wild type (WT) mice (Lee et al.,
2018). When placed on a HFD, there was no difference between the Panx1-KO and WT
mice in either weight gain or obesity blood markers, but there was an increase in glucose
and insulin levels in the Panx1-KO mice (Lee et al., 2018). The similarity in weight gain
may be due to the higher activity level observed in the Panx1-KO mice, with higher
ambulatory activity and reduced sleep duration (Lee et al., 2018). Furthermore, skin tissue
samples were collected from the fat pads of the Panx1-KO mice on the normal and HFD
(Lee et al., 2018). Hematoxylin and eosin staining revealed that the absence of Panx1
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increased adipocyte size and reduced the number of adipocytes in subcutaneous adipose
tissue, which is typical of obese patients (Lee et al., 2018). In terms of differentiation,
Panx1 has been reported to inhibit murine adipogenesis (Lee et al., 2018). ASCs isolated
from a Panx1-KO mouse had increased levels of adipocyte markers, including increased
oil red O content, GPDH activity, and secretion of adiponectin and leptin (Lee et al., 2018).
Since PANX1 is also expressed in human ASCs, there is a possibility that PANX1 inhibits
human adipogenesis, however further studies are required.
1.5

Rationale and Hypothesis

Pannexin 1 has been reported to play a role in murine adipogenesis and adipocyte function,
and is clearly expressed in human MSCs (Guerrero et al., 2018; Lee et al., 2018). However,
it is unclear whether PANX1 plays a role in human adipogenesis, and therefore we aimed
to investigate the role of PANX1 during human MSC differentiation into adipocytes. Since
MSC origin has an influence on differentiation, we used MSCs derived from iPSCs (further
referred to in this report as iMSCs) and ASCs (MSCs collected from human adipose tissue)
to investigate the role of PANX1 during adipogenesis. We hypothesized that PANX1
regulates human MSC directed in vitro adipogenesis.
1.6

Objectives

The specific aims of this project were to:
1.6.1 Determine PANX1 mRNA and protein levels as iMSCs and ASCs differentiate along
the adipogenic lineage.
1.6.2 Examine the effects of pharmacological inhibition of PANX1 channel function and
PANX1-ablation on iMSCs during adipogenesis.
1.6.3 Investigate the effects of pharmacological inhibition of PANX1 channel function on
ASC differentiation along the adipogenic lineage.
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Chapter 2

2

The Role of Pannexin 1 during Human Adipogenesis in vitro

Pannexin 1, a channel forming protein, has been reported to play a role in murine
adipogenesis and fat accumulation. However, it is not known whether human pannexin 1
(PANX1) plays a role in adipogenesis. Here we study for the first time the role of PANX1
during adipogenesis in vitro using two sources of human mesenchymal stem cells (MSCs):
adipose derived stem cells (ASCs), and induced MSCs (iMSCs) which were derived from
induced pluripotent stem cells (iPSCs). Using a clustered regularly interspaced short
palindromic repeat associated caspase 9 (CRISPR/Cas9) gene ablations strategy, we found
that PANX1 was not necessary to differentiate iPSCs into iMSCs, suggesting that PANX1
does not play a role in this early state of stem cell differentiation. Immunoblotting revealed
that PANX1 was expressed in both the ASCs and iMSCs; however, PANX1 levels did not
change during in vitro adipogenesis, which was induced using a previously published
adipogenic media and the StemPro Adipogenesis Differentiation Kit respectively. Both the
ASCs and iMSCs were treated with a PANX1-channel blocker, either carbenoxolone or
probenecid, during adipogenic induction. Carbenoxolone was able to inhibit later stages of
adipogenesis in both the iMSCs and the ASCs, as indicated by the lack of lipid droplet
formation and glycerol-3-phosphate dehydrogenase (GPDH) activity, as well as reduced
levels of adipogenic mRNA markers, LPL (encoding for lipoprotein lipase) and ADIPOQ
(encoding for adiponectin). Determined by the same adipogenic parameters, probenecid
was only able to halt later stages of adipogenesis in the iMSCs, and not able to halt it in the
ASCs. The different responses from the two cell types to probenecid indicates that MSCs
from different sources have distinct characteristics. Furthermore, PANX1-ablated iPSCs,
generated using CRISPR/Cas9, were capable of transitioning into iMSCs based on surface
marker expression. Furthermore, PANX1-ablated iMSCs expressed similar levels of lipid
droplet formation, glycerol-3-phosphate dehydrogenase (GPDH) activity, and adipogenic
marker mRNA levels to control iMSCs when induced along the adipogenic lineage.
Overall, PANX1 appears to be dispensable for in vitro human adipogenesis, despite being
expressed in both ASCs and iMSCs.
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2.1

Introduction

According to the World Health Organization, about 10% of the global population is
estimated to be obese (World Health Organization, 2014). Obesity is characterized by an
accumulation of excess adipose tissue, which results in adipose dysfunction (Hajer et al.,
2008; Castro et al., 2014). This leads to a chronic low-grade inflammation that can develop
into insulin resistance and type 2 diabetes (Tao & Lagergren, 2013; Hruby & Hu, 2015).
Adipose tissue is predominantly made of adipocytes, which perform endocrine functions,
tissue repair, protection against mechanical stress, and, most importantly, lipid storage
(Cohen & Spiegelman, 2016). During excessive consumption, adipocytes accommodate
for the overflow of lipids by expanding in one of two ways: hypertrophy (increase in cell
size) or hyperplasia (increase in the number of cells) (Ghaben & Scherer, 2019). Studies
have shown that, during obesity, adipocytes undergo hypertrophy to store the excess lipids
(Gesta et al., 2007). The larger cell sizes result in mechanical stress, which causes hypoxia
and induces inflammation (Coelho et al., 2013; Ghaben & Scherer, 2019). It is believed
that promoting hyperplasia in adipocytes would help to distribute the excess lipids among
more cells, with the benefit of also maintaining smaller adipocyte cell sizes.
Adipocytes originate from a multipotent stem cell called mesenchymal stem cells (MSCs)
(Lowe et al., 2011). MSCs can differentiate into adipocytes, chondrocytes, fibroblasts, and
osteoblasts (Strioga et al., 2012). MSCs can be isolated from multiple sources, including
bone marrow and adipose tissue (Wei et al., 2013). Previous studies have shown that MSCs
have a preference to differentiate into cells from their tissue of origin rather than other cell
types (Gimble et al., 2008; Mohamed-Ahmed et al., 2018). For instance, bone marrow
MSCs (BM-MSCs) have been shown to prefer differentiation into chondrocytes and
osteoblasts, but have a lesser capacity to differentiate into adipocytes (Mohamed-Ahmed
et al., 2018). This is true in reverse for adipose derived stem cells (ASCs) (MohamedAhmed et al., 2018). Nevertheless, both these MSCs have a finite replication capacity, and
at high passages (~8-12) these cells enter senescence (Wagner et al., 2008). Hence, MSCs
must be harvested on a frequent basis to maintain a consistent supply. A novel approach to
creating an infinite supply of MSCs is to differentiate induced pluripotent stem cells
(iPSCs) into MSCs (Hynes et al., 2014). iPSCs are somatic cells that have been
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reprogrammed to become pluripotent stem cells capable of infinite renewal, and therefore
iPSCs can be an endless source of MSCs (Hynes et al., 2016). Also, MSCs derived from
iPSCs (iMSCs) are able to differentiate into adipocytes, chondrocytes, and osteoblasts,
though with a preference towards chondrocytes and osteoblasts (Lian et al., 2010; Sheyn
et al., 2016).
Adipogenesis is the differentiation process of MSCs entering the adipogenic lineage to
become adipocytes (Lowe et al., 2011). This process can be divided into two stages:
commitment and differentiation (Ghaben & Scherer, 2019). During the commitment stage,
MSCs transition into pre-adipocytes and become committed towards the adipogenic
lineage (Farmer, 2006; Cristancho & Lazar, 2011; Cawthorn et al., 2012b). Throughout the
differentiation stage, preadipocytes undergo a transcriptional cascade that leads to the
upregulation of proadipogenic factors, peroxisome proliferator-activated receptor gamma
(PPARγ) and CCAAT enhancer binding protein alpha (CEBPα) (Lowe et al., 2011). Both
these transcription factors induce the expression of adipogenic genes necessary for the
performance of adipogenic functions such as lipid storage, insulin sensitivity, and
adipokine secretion (Lowe et al., 2011).
Recently, pannexin 1 has been reported to play a role during differentiation (Celetti et al.,
2010; Langlois et al., 2014; Lee et al., 2018). Pannexins are a family of channel forming
proteins that have four transmembrane domains, with the N-terminus and C-terminus
facing the cytosol (Penuela et al., 2013). Pannexin 1 is glycosylated and trafficked to the
cell surface, where it forms a large pore channel which allows the passage of molecules up
to 1 kDa in size, an example being ATP (Penuela et al., 2013). In rat epidermal
keratinocytes an overexpression of pannexin 1 resulted in keratinocyte dysregulation,
which resulted in impaired epidermal architectures (Celetti et al., 2010). However, human
pannexin 1 (PANX1) was shown to promote human skeletal myoblast differentiation
towards skeletal muscle cells (Langlois et al., 2014). From these studies, it appears that
pannexin 1 can promote or inhibit differentiation according to the cell type. Pannexin 1 has
also been reported to inhibit murine adipogenesis (Lee et al., 2018). Murine ASCs isolated
from pannexin 1-knockout (Panx1-KO) mice had increased adipogenesis, as indicated by
the increase in lipid droplet formation, glycerol-3-phosphate dehydrogenase (GPDH)
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activity, and secretion of adipokines, leptin, and adiponectin (Lee et al., 2018). So far,
PANX1 has also been detected in human ASCs; however, it is unknown whether PANX1
plays a role in human adipogenesis.
Here, for the first time, we determined if PANX1 influences human adipogenesis in vitro
by both pharmacologically inhibiting PANX1 channel function and genetically ablating
PANX1. We investigated the role of PANX1 in two human MSC models: ASCs and
iMSCs. Based on the findings in the murine model, we hypothesized that PANX1 does
play a role in human adipogenesis in vitro. In this study, we found that the MSC models
had different responses to probenecid, suggesting that MSCs from different sources have
distinct characteristics. Furthermore, it appears that PANX1 was not necessary during
human adipogenesis, indicating that PANX1 may not be an ideal target to regulate
adipogenesis for treating adipose-related diseases.
2.2

Materials and Methods

2.2.1

iPSC and MSC Culture and Differentiation

Human dermal fibroblasts and the cells derived from them were included on an approved
and continuing University of Western Ontario, Human Research Ethics Board protocol
(#104190). Previously, human dermal fibroblasts from a 30-year old female were
reprogrammed into iPSCs by the Centre for the Commercialization of Regenerative
Medicine (CCRM; Toronto, ON, Canada) (Esseltine et al., 2017). The iPSCs were cultured
in TeSR™-E8™ Media (StemCell Technologies; Vancouver, BC, Canada; #05990) on
Gel-Trex-coated dishes (ThermoFisher Scientific; Waltham, MA, USA; #A1413302) and
passaged using Gentle Cell Dissociation buffer (ThermoFisher Scientific; Waltham, MA,
USA; #13151014) before reaching 80% confluency. For transfection, the iPSCs were
reverted to a naïve-like state by culturing the iPSCs in RSet Media (StemCell
Technologies; Vancouver, BC, Canada; #05970) on 0.1% gelatin and mouse embryonic
fibroblasts (MEFs) at 37°C in a hypoxic incubator (5% CO balanced with nitrogen). Naïve2

like iPSCs were split using TrypLE (ThermoFisher Scientific; Waltham, MA, USA;
#12605010) and reverted to primed iPSCs by returning the naïve-like cells to TeSR™E8™ Media on Gel-Trex-coated dishes.
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The iPSCs were further differentiated into bona fide iMSCs using the STEMdiff™
Mesenchymal Progenitor Kit (StemCell Technologies; Vancouver, BC, Canada; #05240).
The iMSCs were maintained in MesenCult™ MSC Basal Medium (StemCell
Technologies; Vancouver, BC, Canada; #05401) on 0.1% gelatin-coated plates (StemCell
Technologies; Vancouver, BC, Canada; #07903) and split using the ACF Enzymatic
Dissociation Solution (StemCell Technologies; Vancouver, BC, Canada; #05427) and
ACF Inhibitor Solution (StemCell Technologies; Vancouver, BC, Canada; #05428). Cells
were split before reaching 80% confluency to retain multipotent characteristics, and cells
under passage 12 were used.
The iMSCs were plated at 10,000 cells/cm2 on 0.1% gelatin-coated plates and
differentiated into adipocytes using the StemPro Adipogenesis Differentiation kit
(ThermoFisher Scientific; Waltham, CA, USA; #A1007001) for 14 days. For experiments
investigating the control and PANX1-ablated iMSCs, the iMSCs were induced to
differentiate 24 hours after plating, and non-induced cells were collected immediately prior
to induction. For the experiments studying the effects of probenecid and carbenoxolone on
adipogenesis, iMSCs were induced to differentiate once the cells were 100% confluent
(approximately 72 hours after plating), and non-differentiated iMSCs were cultured in
parallel with MesenCult™ MSC Basal Medium without adipogenesis induction. iMSCs
were induced in either the absence or presence of either 50 μM carbenoxolone (SigmaAldrich; Oakville, ON, Canada; # C4790) or 1 mM of probenecid (ThermoFisher
Scientific; Waltham, CA, USA; #P36400). Throughout culturing, the iPSCs and iMSCs
were incubated with 100 penicillin units/mL and 0.1 mg/mL streptomycin (ThermoFisher
Scientific; Waltham, CA, USA; #15140-122). The iPSCs (except for the naïve-like iPSCs)
and iMSCs were cultured at 37°C with 5% CO throughout the experiment.
2

2.2.2

ASC Culture and Differentiation

Human ASCs from abdominal and breast fat tissue obtained from female donors (age 23
to 72 with a body mass index range of 28.5 to 41.2) were isolated and maintained in the
laboratory of Dr. Lauren Flynn (under an approved University of Western Ontario, Human
Research Ethics Board protocol (105426) to Dr. Lauren Flynn) (Flynn, 2010) and
generously provided for these studies. The ASCs were cultured in ASC growth medium:
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Dulbecco's Modified Eagle Medium: Ham’s F12 (DMEM: Ham’s F12) with 10% fetal
bovine serum (FBS), 100 penicillin units/mL and 0.1 mg/mL streptomycin (Flynn, 2010;
Yu et al., 2017; Lee et al., 2018) at 37°C with 5% CO throughout the experiments. Passage
2

3 ASCs were plated at 50,000 cells/cm2 and stimulated to differentiate into adipocytes in
the presence of DMEM: Ham’s F12 with 33 μM biotin, 17 μM pantothenate, 10 μg/mL
transferrin, 1000 nM hydrocortisone, 66 nM human insulin, 1 nM triiodothyronine, 0.25
mM isobutylmethanlxanthine (IBMX), 1 μg/mL troglitazone, 100 penicillin units/mL and
0.1 mg/mL streptomycin for the first three days (Flynn, 2010). For the last four days,
induced cells were cultured in DMEM: Ham’s 12 with 33 μM biotin, 17 μM pantothenate,
10 μg/mL transferrin, 1000 nM hydrocortisone, 66 nM human insulin, 1 nM
triiodothyronine, 100 penicillin units/mL and 0.1 mg/mL streptomycin (Flynn, 2010). All
media components were obtained from Sigma-Aldrich (Oakville; ON, Canada). In some
cases, ASCs were differentiated in either the absence or presence of either 50 μM
carbenoxolone or 1 mM of probenecid. As a control, ASCs were maintained in ASC growth
media without adipogenesis induction during the seven-day differentiation period.
2.2.3

Adherent Human Embryonic Kidney 293 (AD293) Cell Culture and
Transfection

AD293 were used as positive PANX1 controls. These cells were obtained from Agilent
Technologies (Santa Clara, CA, USA) were cultured in DMEM (ThermoFisher Scientific;
Waltham, CA, USA; # 11965-092) supplemented with 5% FBS, 2 mM L-glutamine
(ThermoFisher Scientific; Waltham, CA, USA; #25030-081), 100 penicillin units/mL and
0.1 mg/mL streptomycin (ThermoFisher Scientific; Waltham, CA, USA; #15140-122).
Cells

were

split

before

reaching

90%

confluency

using

0.25%

trypsin-

ethylenediaminetetraacetic acid (EDTA) (ThermoFisher Scientific; Waltham, CA, USA;
#25200-056). The human PANX1 overexpression AD293 cells, generated by Daniel
Nejad, a master’s candidate in Dr. Silvia Penuela’s lab, were used as a positive control.
The AD293 cells were grown to 60-70% confluence, then transiently transfected with 1 ug
pUNO1-hPANX1

(InvivoGen;

San Diego,

CA, USA;

#puno1-hpanx1) using

Lipofectamine 3000 (ThermoFisher Scientific; Waltham, CA, USA, #L3000015) as
previously described (Shao et al., 2016). Protein lysates were collected 72 hours after
transfection.
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2.2.4

Genetic Ablation of PANX1

PANX1-ablated iPSCs and AD293 cells were generated by Dr. Jessica Esseltine using
CRISPR/Cas9. Two pairs of guide RNAs (gRNAs) were designed using the
www.sanger.ac.uk website that specifically targeted the PANX1 gene (Table 1). The first
pair targeted the first exon of PANX1 and was used to ablate PANX1 function in AD293
cells; however, there was a slightly higher chance for off-target effects using this pair of
gRNAs. To address this, the second pair of gRNAs, which has a lower chance of off-target
effects, was used to target the third exon of PANX1 to ablate PANX1 function in the naïvelike iPSCs.
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Table 2.1 Guide RNAs Used to Ablate PANX1 with Clustered Regularly Interspaced Short
Palindromic Repeat Associated Caspase 9
Cell Type AD293

iPSCs

Sanger
Sequence

1087076273

1087081842

Forward

CACCGTTCTCGGATTTCTTGCT
GA

CACCGCTGCGAAACGCCAGAA
CAG

Reverse

AAACTCAGCAAGAAATCCGAG AAACCTGTTCTGGCGTTTCGCA
AAC
GC

Exon
Target

Exon 1

Exon 3

Structure
Target

first transmembrane domain

second transmembrane domain and
the intracellular loop
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The gRNAs were ordered from the UWO OligoFactory (London, ON, Canada) and cloned
into a pSpCas9(BB)-2A-GFP plasmid (Addgene; Watertown, MA, USA; # PX458) that
encodes for the caspase-9 protein and green fluorescent protein (GFP). AD293 and naïvelike iPSCs were transfected with 2 μg of gRNA PX458 vector at a 1:6 dilution with Mirus
TransIT®-LT1 Reagent (Mirus Bio LLC; Madison, WI, USA; #MIR 2300) according to
manufacturer’s instructions. Using Flow-Activated Cell Sorting (FACS) with the BD
FACSAria III (BD Biosciences; Mississauga, ON, Canada), successfully transfected cells
were identified by GFP expression and were individually plated either on tissue-cultured
treated plastic (AD293) or on MEFs (naïve-like iPSCs). The naïve-like iPSC clones were
returned to the primed iPSC state and differentiated into MSCs. AD293 cells engineered
to have functional PANX1 deleted were immunoblotted for the presence of PANX1 and
MSCs were subjected to PANX1 DNA gene sequencing to confirm gene editing.
2.2.5

DNA Sequencing

Primers that flanked the CRISPR/Cas9 cut site were designed using PrimerBlast and were
predicted to produce a polymerase chain reaction (PCR) product of 579 base pairs
(Forward: CGCAGGAGATCTCGATTGGT; reverse: TGCTGCACACAAACTCGTCT).
Total RNA was isolated from the MSCs and its derivatives using the QIAshredder (Qiagen;
Germantown, MD, USA) and RNeasy Mini Kit (Qiagen; Germantown, MD, USA).
Reverse transcription was executed using the Superscript VILO cDNA Synthesis Kit
(ThermoFisher Scientific; Waltham, MA, USA) according to manufacturer’s instructions,
using 500 ng of RNA. Reactions were incubated in a MyCycler Thermal Cycler (Bio-Rad,
Hercules, CA, USA) for 25°C/10 min, 42°C/60 min, and then 85°C/5 min. The
complementary DNA (cDNA) products were amplified using REDTaq Ready Mix (SigmaAldrich; Oakville, ON, Canada; #R2523) with a 20 μL reaction volume in a MyCycler
Thermal Cycler (Bio-Rad, Hercules, CA, USA) for 94°C/3 min, and then 25 cycles of
94°C/30 s and 52°C/30 s and 72°C/30 s, followed by 72°C/7 min. PCR products were
separated on a 1% agarose gel, and extracted using the QIAquick Gel Extraction Kit
(Qiagen; Germantown, MD, USA; #28704). These PCR products were sequenced by the
DNA Sequencing Facility at Robarts Research Institute (London, ON).
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2.2.6

Characterization of MSCs Using Flow Cytometry

According to the International Society of Cell Therapy, multipotent MSCs must express
specific surface markers: ≥95% positive for CD73, CD90 and CD105 and ≤2% positive for
CD34 and CD45. The following anti-human antibodies were purchased: CD34 eFluor 450
(1 µg/100 µL; ThermoFisher Scientific; Waltham, CA, USA; #48-0349-42), CD45 APC
(0.25 µg/100 µL; ThermoFisher Scientific; Waltham, CA, USA; #17-9459-41), CD73
FITC (0.25 µg/100 µL; ThermoFisher Scientific; Waltham, CA, USA; #11-0739-42),
CD90 (4 µL/100 µL; Molecular probes; Waltham, MD USA; #A15761) and CD105 (1
µg/100 µL; Invitrogen; CA, USA; #12-1057-42). MSCs were harvested and incubated as
a single cell-suspension for thirty minutes at 4°C in the dark with antibodies diluted in
phosphate buffered saline (PBS) supplemented with 5% FBS, according to the
manufacturer’s instructions. Stained and unstained samples were immediately analyzed
with single colour flow cytometry using the BD FACSCanto™ II system (BD Biosciences;
Mississauga, ON, Canada) and the BD FACSDiva™ software (BD Biosciences;
Mississauga, ON, Canada) with a minimum of 10,000 events recorded for each sample.
Similarly, isolated ASCs were analyzed for surface markers using single color flow
cytometry with the Guava easyCyte 8HT Benchtop flow cytometer (EMD Millipore;
Burlington, MA, USA; #0500-4008), following the previously mentioned methods (Yu et
al., 2017). In brief, cells were lifted using EDTA-trypsin and incubated for thirty minutes
in the dark on ice with anti-human antibodies diluted in PBS supplemented with 5% FBS.
The following anti-human antibodies (purchased from ThermoFisher Scientific; Waltham,
CA, USA) were used: CD105 PE (1 µg/100 µL; #12-1057-41), CD90 FITC (0.25 µg/100
µL; #15-0909-42), CD73 FITC (0.25 µg/100 µL; #11-0739-41), CD34 APC (0.25 µg/100
µL; #17-0349-41), and CD45 FITC (0.25 µg/100 µL; #11-0459-41). Stained and unstained
samples were included in the analysis. ASC characterization via flow cytometry was
performed by the members of the Flynn Lab, and only cells that demonstrated hallmark
characteristics of stem cells were used in adipogenesis studies.
2.2.7

MSC Growth Curve

To determine if probenecid caused unexpected MSC cell death, control iMSCs were plated
at 2,500 cells/cm2 on 0.1% gelatin-coated plates and incubated in MesenCult Basal Media
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supplemented with 0 μM, 1 μM, 10 μM, 100 μM, and 1 mM probenecid. Media
supplemented with probenecid was replenished every other day for two weeks. Images
were acquired using a Leica DMI6000B Inverted Fluorescent Microscope (Leica
Microsystems Inc.; Concord, Ontario Canada) to visually assess for any evidence of cell
death.
To measure cell growth, control and PANX1-ablated MSCs were plated at 2,500 cells/cm

2

on 0.1% gelatin-coated plates. Cells were maintained in MesenCult Basal Media with or
without 1 mM probenecid for up to fourteen days, with media changes every other day.
Cells were stained with Trypan Blue Stain (0.4%) (ThermoFisher Scientific; Waltham, CA,
USA; #T10282) and counted every two days using the Countess® Automated Cell Counter
(ThermoFisher Scientific; Waltham, CA, USA; #10227).
2.2.8

Quantitative PCR

Reverse transcription was completed using the Superscript VILO cDNA Synthesis Kit
(ThermoFisher Scientific; Waltham, MA, USA) according to the manufacturer’s
instructions, using 400 ng of RNA. Quantitative assessment of mRNA levels was
performed using PowerUp SYBR Green Master Mix (ThermoFisher Scientific; Waltham,
MA, USA) according to the manufacturer’s instructions with 10 μL reactions containing 5
nM forward primer, 5 nM reverse primer, and 0.5 μL cDNA. qPCR was performed in either
a CFX96 Real-Time System (Bio-Rad, Hercules, CA, USA) or a CFX384 Real-Time
System (Bio-Rad, Hercules, CA, USA) with the following settings: 50°C/2 min, 95°C/2
min, and then 40 cycles going between 95°C/15 s and 58.5°C/30 s. Relative mRNA levels
were calculated using the delta-delta CT method.
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Table 2.2 Human Gene-Specific Primers for Quantitative Polymerase Chain Reaction
Gene

Reverse

Forward

18S

GTAACCCGTTGAACCCCATT

CCATCCAATCGGTAGTAGCG

PANX1

GGCAAAACTCCCATGTCTGC

CAGAAGTCTCTGTCGGGCAT

GADPH

CTGGGCTACACTGAGCACC

AAGTGGTCGTTGAGGGCAATG

ADIPOQ

AACATGCCCATTCGCTTTACC

TAGGCAAAGTAGTACAGCCCA

LPL

GTCCGTGGCTACCTGTCATT

TGGCACCCAACTCTCATACA

CEBPα

CAGAGGGACCGGAGTTATGA

TTCACATTGCACAAGGCACT
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2.2.9

Immunoblotting

Cell lysates were collected using 1x immunoprecipitation buffer (2% Triton X-100, 330
mM NaCl, 20 mM Tris, 2 mM EDTA, 2 mM ethylene glycol-bis(β-aminoethyl ether)N,N,N′,N′-tetraacetic acid, 1% NP-40, pH 7.4) supplemented with a cOmplete™, Mini
Protease Inhibitor Cocktail tablet (Millipore Sigma; Burlington, MA, USA; #11836153001
ROCHE), 1:100 sodium fluoride and 1:100 sodium orthovanadate phosphatase inhibitors.
Cell lysates from AD293 cells overexpressing PANX1 were collected 72 hours post
transfection. The cell lysates were stored at -80°C until they were analyzed and were
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) on
a 10% SDS-gel before being transferred to a nitrocellulose membrane using the iBlot® Dry
Blotting System (Life Technologies, Waltham, CA, USA). The membrane was blocked
with 3% bovine serum albumin (BSA) diluted in PBS Tween for one hour at room
temperature, and then incubated overnight on a rocker at 4°C with either 1 ng/μlcustommade rabbit anti-human PANX1 targeting the C-terminus of PANX1 (Shao et al., 2016),
1:1000 rabbit anti-PPARγ (Cell Signaling Technology; Davers, MA, USA; #2435), or
1:5000 rabbit anti-human Cx43 (Sigma-Aldrich; Oakville, ON, Canada; #C6219),
followed by one hour incubation on a rocker at room temperature with 1:5000 dilution of
goat anti-rabbit Alexa Fluor 680 secondary antibody (ThermoFisher Scientific; Waltham,
MA, USA; #A21076). The membrane was also blotted at room temperature with 1:5000
mouse anti-human GAPDH (EMD Millipore; Burlington, MA, USA; #A21076) for one
hour, and then 1:5000 dilution of Infrared Fluorescent Dye 800 goat anti-mouse antibody
(Rockland; PA, USA; #611-132-122) for one hour. Membrane imaging was performed
using the Odyssey Infrared Imaging System (Li-Cor BioSciences; Lincoln, NE, USA).
2.2.10 Confocal Imaging
Immunofluorescence was performed to determine the cellular localization of PANX1,
PPARγ and perilipin. Cells were grown on glass coverslips covered in 0.1% gelatin and
fixed with either 80% methanol, 20% acetone for fifteen minutes or with 10% neutral
buffered formalin for thirty minutes at room temperature. The cells were covered with
blocking solution (2% BSA with 0.1% Triton X-100) for one hour, followed by a one-hour
incubation at room temperature in one of the following primary antibodies: 2 ng/μl dilution
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of custom-made rabbit anti-human PANX1 directed to the C-terminal of the polypeptide
(Shao et al., 2016), 1:100 dilution of rabbit anti-human PPARγ (Cell Signaling
Technology; Danvers, MA, USA; #2435), or 1:200 dilution of rabbit anti-human perilipin
(Cell Signaling Technology; Danvers, MA, USA; #9349). Primary antibody binding was
detected with 1:500 dilution of donkey anti-rabbit Alexafluor 488 (Invitrogen; Waltham,
CA, USA; #A21206) and/or 1:200 dilution of HCS LipidTOX™ Green neutral lipid stain
(ThermoFisher Scientific; Waltham, CA, USA; #H34475). To stain cell nuclei, cells were
labelled with 1:1000 dilution of Hoechst (ThermoFisher Scientific; Waltham, CA, USA;
#H3570) for five minutes in the dark at room temperature. Coverslips were mounted on
glass slides using Airvol (made in house), left to dry for at least eight hours at 4°C, and
then imaged with a Zeiss LSM800 Confocal Microscope equipped with Airyscan (Zeiss;
Toronto, Ontario, Canada).
Lipid

droplet

formation

was

quantified

and

analyzed

using

ImageJ

(https://imagej.nih.gov/ij/). In brief, three to ten immunofluorescent images (165.2 μm x
165.2 μm) per biological replicate were captured, and the investigators were blinded to the
treatment during data analysis to avoid bias. First, the number of differentiated cells per
image was recorded as identified by the presence of lipid droplets. Second, the images were
split into separate red, blue, and green channels. Lipid (green channel) images were
adjusted to a specific threshold (50-255), and converted to binary images, where lipid
droplet content (% lipid area in the total image) and average lipid size was measured.
Similarly, nuclei (blue channel) images were adjusted to a specified threshold (43-255) and
converted to binary images. Particles (nuclei) larger than 50 μm2 were counted. The ratio
of lipid droplet content per nuclei, average lipid size per nuclei, and the number of cells
that differentiated per nuclei was calculated for each image.
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Figure 2.1 Experimental Procedure for Lipid Droplet Quantification via ImageJ
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Figure 2.1: Experimental Procedure for Lipid Droplet Quantification via ImageJ. Confocal

images were split into the green, blue, or red channel. (A) Lipid droplet content and average
lipid droplet size were calculated using images from the green channel. (B) Nuclei were
counted from blue channel images.
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2.2.11 Oil Red O Staining
After seven days of culturing in differentiation medium, ASCs were fixed with 2%
paraformaldehyde for 15 minutes at room temperature. Oil red O is a lysochrome (fat
soluble dye) diazo dye used to stain and visualize lipids droplets, and Oil Red O stock
solution was prepared by dissolving Oil Red O powder (Sigma-Aldrich; Oakville, ON,
Canada; #O0625-100G) in 99.9% isopropanol at 3 g/L. The Oil Red O working solution
was prepared with a 3:2 ratio of Oil Red O Stock Solution to deionized water and filtered
through a Whatman type 2 filter paper (Sigma-Aldrich; Oakville, ON, Canada; #1002917). The cells were stained for five minutes at room temperature, followed by a
hematoxylin counterstain (Sigma-Aldrich; Oakville, ON, Canada; #GHS116-500ML) for
two minutes at room temperature (Turner et al., 2012). Images were taken using an
EVOS® XL Core imaging system (Fisher Scientific, Ottawa, ON, Canada).
2.2.12 GPDH Activity
A GPDH Activity Kit (Kamiya Biomedical Inc.; Tukwila, WA, USA; Cat. # KT-010) was
used to quantify GPDH activity, which was normalized to total protein content as measured
by the Bio-Rad protein sample assay (Bio-Rad; Hercules, CA, USA) which included
albumin standards (Turner et al., 2012). In brief, the substrate reagent contained
dihydroxyacetone phosphate (DHAP) and NADH (a co-enzyme for GPDH). NADH
concentration decreased as DHAP was converted into glycerol-3-phosphate by GPDH,
which was measured by spectrophotometry at 340 nm absorbance over a period of 10
minutes at room temperature. The change in absorbance (Δ Optical Density/min) was
determined from the slope of the kinetic curve. Data is shown in mUnits/mg intracellular
protein (mU/mg), where one unit is defined as the GPDH activity necessary to oxidize one
μmol of NADH per min.
2.2.13 Statistical Analysis
Three or more biological replicates were analyzed using a two-tailed unpaired Student’s
T-test, or a two-way unpaired ANOVA with Tukey’s post hoc test. A p-value less than
0.05 was considered significant. Data from GPDH activity assays and lipid droplet
quantification (total lipid content per nuclei, average lipid size per nuclei, and the number
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of cells differentiated per nuclei) were square root transformed prior to statistical analysis.
Statistical analysis was done using GraphPad Prism 7 (GraphPad Software; CA, USA).
2.3

Results

2.3.1

PANX1 mRNA Levels, but Not Protein Levels, Increased during
Adipogenesis

To study PANX1 mRNA levels during adipogenesis, iMSCs were first induced to
differentiate along the adipogenic lineage. Formation of lipid droplets revealed that a
population of iMSCs had successfully differentiated along the adipogenic lineage after
fourteen days (Figure 2.2). Immunolabeling for PANX1 failed to detect PANX1 in either
undifferentiated or differentiated iMSCs while PANX1 was readily detected in wild type
(WT) AD293 cells, but absent in AD293 cells engineered to ablate the expression of
PANX1 protein (PANX1-ablated AD293) (Figure 2.2). After fourteen days of
differentiation, induced iMSCs exhibited a significant increase in PANX1 mRNA
compared to non-induced iMSCs (p<0.05) (Figure 2.3A). However, there was no
significant difference in the levels of the combined Gly0, Gly1 and Gly2 species of
PANX1, which represent different states of glycosylation (Figure 2.3B, C).
After seven days of culturing in adipocyte induction media, a population of ASCs
differentiated along the adipogenic lineage, indicated by the presence of lipid droplets
(Figure 2.4A). PANX1 mRNA levels increased in induced ASCs compared to non-induced
ASCs (p<0.05) (Figure 2.4B); however, PANX1 protein levels (combined Gly0, Gly1 and
Gly2 species) did not change between non-induced and induced control ASCs (Figure
2.4C, D). Furthermore, iMSCs had a lower level of PANX1 protein expression compared
to ASCs, under both non-induced (Figure 2.5A) and induced conditions (Figure 2.5B). This
indicates that even though both cell types can undergo adipogenesis, PANX1 protein levels
were significantly different (p<0.05).

53

Figure 2.2 PANX1 Protein Was Not Observed in iMSCs
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Figure 2.2: PANX1 Protein Was Not Observed in iMSCs. Control iMSCs were induced to
differentiate to adipocytes for 14 days. PANX1 protein was not detected in non-induced
and induced iMSCs. WT AD293 cells expressed PANX1 protein (red) but PANX1 was
absent in the PANX1-ablated AD293 cells. Lipid droplets were observed in the induced
iMSCs via staining with the HCS LipidTOX™ Green (green), indicating that adipogenesis
was occurring. Nuclei were stained blue with Hoechst. Representative images of N=3.
Scale bar = 20 μm.
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Figure 2.3: PANX1 mRNA and Protein Levels during iMSC Adipogenesis
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Figure 2.3: PANX1 mRNA and Protein Levels during iMSC Adipogenesis. Control iMSCs
were induced to differentiate along the adipogenic lineage for 14 days. (A) PANX1 mRNA
levels were significantly increased in induced compared to non-induced iMSCs. (B)
PANX1 protein levels did not significantly change between the non-induced and induced
cells. (C) Representative immunoblot shows PANX1 protein levels between non-induced
and induced iMSCs. The three glycosylation states of PANX1 (Gly0, Gly1 and Gly2) are
noted. WT AD293 and PANX1-ablated AD293 cells were used as positive and negative
controls respectively. Data shown are the mean of three or four independent trials ± SEM.
*, p<0.05 (Two-tailed Student’s T-Test). qPCR samples were provided by Tao Huang.
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E)

Figure 2.4 PANX1 mRNA and Protein Levels during ASC Adipogenesis
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Figure 2.4: PANX1 mRNA and Protein Levels during ASC Adipogenesis. ASCs were
induced to differentiate along the adipogenic lineage for seven days. (A) Lipid droplets
were observed in the induced ASCs via Oil Red O staining; no lipid droplets were noted in
the non-induced ASCs. Representative brightfield images taken from four trials. Scale bar
= 200 μm (B) PANX1 mRNA levels significantly increased during cell differentiation. (C)
There was no significant difference in PANX1 protein levels between the non-induced and
induced cells. (D) Representative immunoblot of PANX1 found in non-induced and
induced ASCs. Wild type AD293 and PANX1-ablated AD293 cells were used as positive
and negative controls, respectively. (E) Table listing the body mass index (BMI), age of
each donor and tissue origin (abdominal (abd.) or breast). Data shown are the average
protein levels of three independent trials ± SEM. *, p<0.05 (Two-tailed Student’s T-Test).
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Figure 2.5 ASCs Had Significantly Higher PANX1 Protein Levels
Compared to iMSCs
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Figure 2.5: ASCs Had Significantly Higher PANX1 Protein Levels Compared to iMSCs.
iMSCs were differentiated along the adipogenic cell lineage for 14 days with StemPro
Adipogenesis Differentiation Media, while ASCs were induced for seven days with ASC
Adipocyte induction media. ASCs had significantly higher PANX1 protein levels
compared to iMSCs, when normalized to GAPDH, in both the non-induced (A) and
induced (B) condition. Data shown are the average protein levels of three to four
independent trials ± SEM *, p<0.05; **, p<0.01 (Two-tailed Student’s T-Test).
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2.3.2

Characterization of iMSC Clones with PANX1 Ablated

CRISPR/Cas9 was used to genetically modify the PANX1 gene in iPSCs. Two putative
PANX1 deleted clones (clone 2 and 4) were differentiated into iMSCs and assessed for the
presence of PANX1 via immunoblotting with the anti-human PANX1 antibody. As
expected, PANX1 was detected in the positive controls (WT AD293 cells and AD293 cells
engineered to overexpress human PANX1) but was not detected in the negative control
(PANX1-ablated AD293 cells) (Figure 2.6). Unfortunately, PANX1 protein levels were
sufficiently low that it could not be reliably detected in the unedited cells, raising concerns
as to whether the PANX1 gene was successfully ablated (Figure 2.6). To address this
question, the gene encoding full length PANX1 was sequenced. Based on DNA sequencing
analysis, clone 2 had an eight-base pair deletion causing a frameshift mutation (beginning
at amino acid position 123), resulting in an early stop codon at amino acid position 144
(Figure 2.7B, C). Residue 144 is found within the intracellular loop of the PANX1
polypeptide, thus preventing any possibility for PANX1 to successfully form a functional
channel. Analysis of the DNA sequence indicated that the eight-base pair deletion occurred
in at least one of the PANX1 alleles, resulting in a loss of heterozygosity (Figure 2.7E).
Dr. Jessica Esseltine (Memorial University, St. John’s, NFL) was further able to
independently confirm that PANX1 was ablated from clone 2 iPSCs of which the iMSCs
were derived via immunoblotting (data not shown; personal communication). Due to the
ablation, clone 2 was used for the remainder of the experiments and is further referred as
PANX1-ablated iMSCs. A second clone, clone 4 had a nine base pair deletion that resulted
in a three amino acid deletion (from position 127 to 130, which is located between the
second transmembrane domain and the intracellular loop of the PANX1 polypeptide)
(Figure 2.7B, D). Clone 4 was not used for any further experiments as it was deemed to
express a PANX1 mutant and did not represent cells that were devoid of functional
PANX1.
Control and PANX1-ablated iMSCs expressed >95% CD73, CD90, and CD105, as well as
<2% of the hematopoietic markers CD34 and CD45; therefore, both cell types can be
classified as MSCs according to their surface CD protein expression profile (Figure 2.8).
Furthermore, there was no significant difference in the total number of cells between the

62

Figure 2.6 Representative Western Blot of PANX1 in iMSCs
.
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Figure 2.6: Representative Western Blot of PANX1 in iMSCs. Control (unedited) iMSCs
were found by Western blot to have a low level of PANX1, making it difficult to determine
if PANX1 was ablated from iMSCs that were edited by CRISPR/Cas9 to ablate the PANX1
gene. Wild type AD293 cells were used as a positive control, while PANX1-ablated AD293
cells were used as negative controls. GAPDH was used a gel loading control.
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Figure 2.7 Based on DNA Sequencing, CRISPR/Cas9 Edited Clone 2 iMSCs Resulted
in Truncated PANX1 Protein
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Figure 2.7: Based on DNA Sequencing, CRISPR/Cas9 Edited Clone 2 iMSCs Resulted in
Truncated PANX1 Protein. (A) Experimental schematic demonstrating the location of the
CRISPR/Cas9 cut site and primers in the human PANX1 gene. (B) DNA sequencing
determined there was an eight base pair deletion in clone 2 and a nine base pair deletion in
clone 4. (C, D) Images of control protein sequence from http://www.rcsb.org/ and
highlighted areas indicate sites of mutations. (C) The eight base pair deletion in clone 2
resulted in a frameshift mutation with an early stop codon at position 144 (L123fsX144).
(D) For clone 4, the nine base pair deletion cause a three amino acid deletion (W127_F130).
(E) Analysis of DNA sequencing indicated that clone 2 was heterozygous for the ablation
of PANX1. DNA alignment images from SnapGene Viewer. Arginine (Arg); base pair
(bp); Primer 1 (Prim1); Primer 2 (Prim2); Protospacer adjacent motif (PAM);
Phenylalanine (Phe); Tryptophan (Trp).
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Figure 2.8 PANX1 is Not Necessary for Induced Pluripotent Stem Cell (iPSC)
Differentiation to iMSC
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Figure 2.8: PANX1 is Not Necessary for Induced Pluripotent Stem Cell (iPSC)
Differentiation to iMSCs. PANX1-ablated iPSCs were differentiated into iMSCs and
analyzed for MSC surface markers. As expected for MSCs, PANX1-ablated and control
iMSCs had >95% expression of CD73, CD90 and CD105, as well as <2% expression of
CD34 and CD45.

68

control and PANX1-ablated iMSCs after growing in culture for seven days in MesenCult
Media (Figure 2.9B). Thus, any potential differences in adipogenic capacity cannot be
attributed to differences in growth rates.
2.3.3

PANX1 is Not Necessary for iMSC Differentiation along the
Adipogenic Lineage

To access adipogenic potential of iMSCs with and without PANX1, cells were induced to
differentiate in culture. Based on qPCR results, there was no significant difference between
control induced iMSCs and PANX1-ablated induced iMSCs in CEBPα (early adipocyte
marker) or LPL (mid adipocyte marker) mRNA levels (Figure 2.10A, B). The trend
indicates that the induced iMSCs of both cell types have higher levels of these mRNA
markers compared to their non-induced counterpart (Figure 2.10A, B). The late adipocyte
marker, ADIPOQ, was found at low levels among all the experimental groups (Figure
2.10C) suggesting that these cells never reached full adipocyte status. Furthermore, the
GPDH activity between the control and PANX1-ablated induced iMSCs was not
significantly different (Figure 2.10D), but induced cells lacking PANX1 expressed
significantly higher levels of GPDH compared to their controls.
Control and PANX1-ablated induced iMSCs formed lipid droplets (Figure 2.11A, B), and
expressed PPARγ in the nuclei (Figure 2.11A) and perilipin surrounding the lipid bodies
(Figure 2.11B) suggesting that both cell populations had successfully differentiated along
the adipogenic lineage. It was noted that lipid droplets were observed in only a fraction of
the cell population, indicating that some iMSCs had undergone adipogenesis while others
had not, demonstrating that the stem cells were heterogeneous (Figure 2.12A). Between
the control and PANX1-ablated induced iMSCs, there was no significant difference in the
number of differentiated cells (Figure 2.12B), number of lipid droplets (Figure 2.12C),
lipid droplet content (Figure 2.12D), or average size of lipid droplets (Figure 2.12E). These
results suggest that PANX1 did not alter the fate or extent of iMSC ability to differentiate
along the adipogenic lineage.
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Figure 2.9 No Significant Difference in Growth Rate between the PANX1-Ablated and
Control iMSCs
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Figure 2.9: No Significant Difference in Growth Rate between the PANX1-Ablated and
Control iMSCs. PANX1-ablated and control iMSCs were cultured in Mesencult Basal
Media for seven days. (A) Phase contrast images were taken on the seventh day. Images
shown are representative of N=3. Scale bar = 200 μm. (B) There was no significant
difference in total cell number between PANX1-ablated and control iMSCs over seven
days. Data shown are the average of three independent trials run in duplicate ± SEM. (Twoway ANOVA with post-hoc Sidak's multiple comparisons test).
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Figure 2.10 PANX1-Ablated and Control Induced iMSCs Have Similar Levels of
Adipogenesis-Associated Genes and GPDH Activity
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Figure 2.10: PANX1-Ablated and Control Induced iMSCs Have Similar Levels of
Adipogenesis-Associated Genes and GPDH Activity. PANX1-ablated and control iMSCs
were induced to differentiate along the adipocyte cell lineage for fourteen days. There was
no significant difference in the mRNA levels of (A) CEBPα, (B) LPL, or (C) ADIPOQ
between both of the induced cell types. (D) No significant difference was found in GPDH
activity levels between the induced control and PANX1-ablated iMSCs. Data is shown in
mUnits/mg protein (mU/mg), where one unit is defined as the GPDH activity necessary to
oxidize one μmol of NADH per min. Values shown are the mean of three independent trials
± SEM *, p<0.05 (Two-way ANOVA with post-hoc Tukey’s test).
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Figure 2.11 PANX1 is Not Necessary for iMSC Adipogenesis
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Figure 2.11: PANX1 is Not Necessary for iMSC Adipogenesis. Confocal micrographs of
control iMSCs and PANX1-ablated iMSCs induced to differentiate and labelled for lipid
droplets (A, B), PPARγ (A), or perilipin (B) N=2. Nuclei are stained blue with Hoechst.
Scale bar = 20 μm.
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Figure 2.12 PANX1 Ablation Does Not Affect Lipid Droplet Formation in iMSCs
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Figure 2.12: PANX1 Ablation Does Not Affect Lipid Droplet Formation in iMSCs. Control
and PANX1-ablated iMSCs were induced to differentiate for fourteen days. (A) Lipid
droplets were detected in both induced cells types but were absent in non-induced iMSCs.
N=5, n=3-8. Scale bar = 20 μm. Between the induced control and PANX1-ablated iMSCs,
there was no significant difference in either the number of cells that differentiated per
nuclei (B), the number of lipid droplet per nuclei (C), the lipid droplet content per nuclei
(D) or the average size of lipid droplets per nuclei (E). Data shown are the mean of square
root transformed values ± SEM. N=5, n=3-8. **, p<0.01 (Two-tailed Student’s T-Test or
Two-way ANOVA with Tukey’s post hoc test).
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2.3.4

Pharmacological Inhibition of PANX1 Channel Function Inhibits
Adipogenesis

In addition to assessing the role of PANX1 by using PANX1 ablated iMSCs, we also took
the approach of blocking PANX1 channels using a pharmacological strategy where
probenecid or carbenoxolone was used to inhibit channel function. Based on morphological
assessments, iMSCs were able to tolerate the presence of 1 mM probenecid for fourteen
days (Figure 2.13A). Furthermore, there was no difference in total cell count (relative to
day 0) between the untreated iMSCs and 1 mM probenecid-treated iMSCs over twelve
days (Figure 2.13B).
Control iMSCs were induced to differentiate along the adipogenic lineage in the presence
of either 1 mM probenecid or 50 μM carbenoxolone. Lipid droplets were absent in
undifferentiated cells but were found in induced iMSCs but appeared less prevalent and
smaller in carbenoxolone-treated cells. (Figure 2.14A). Based on qPCR results, when drugfree cells were induced to differentiate, they expressed significantly higher levels of
CEBPα, LPL and ADIPOQ mRNA compared to their non-induced iMSCs counterpart
(p<0.05) (Figure 2.14B, C, D). While not consistently significant, iMSCs induced to
differentiate in the presence of probenecid or carbenoxolone had higher levels of these
same genes compared to their corresponding non-induced iMSCs (Figure 2.14B, C, D).
CEBPα and LPL mRNA levels were comparable between the three induced iMSCs
experimental groups (Figure 2.14B, C). However, induced carbenoxolone-treated iMSCs
had significantly lower ADIPOQ mRNA levels compared to induced drug-free iMSCs
(p<0.05) (Figure 2.14D). Furthermore, while GPDH activity was higher after cells were
induced to differentiate, it was found to be statistically lower in cells induced to
differentiate in the presence of either probenecid or carbenoxolone compared to untreated
(Figure 2.14E). We conclude that PANX1 channel blocking had little effect on the capacity
of iMSC to undergo the early stages of adipogenesis but carbenoxolone was more potent
at blocking later stages of differentiation.
2.3.5

ASC Differentiation Was Partially Inhibited by Carbenoxolone

We next assessed if blocking PANX1 channel function would affect the ability of ASCs to
differentiate along the adipogenic cell lineage. While control and probenecid-treated
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Figure 2.13: Probenecid Had No Effect on iMSC Growth
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Figure 2.13: Probenecid Had No Effect on iMSC Growth. Control iMSCs were cultured in
Mesencult Basal Media in the presence or absence of probenecid for fourteen days. (A)
Control iMSCs were cultured in Mesencult Basal Media with 0 µM, 1 µM, 10 µM, 100
µM or 1 mM probenecid for fourteen days. Phase contrast images shown are representative
of N=3. Scale bar = 200 μm. (B) No significant differences in total cell count were found
between untreated and probenecid-treated iMSCs. Data shown are the average of three
independent trial runs in duplicate ± SEM. (One-way ANOVA with post-hoc Tukey’s test).
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Figure 2.14 Control iMSCs Induced in the Presence of Carbenoxolone Formed Lipid
Droplets, but Exhibited Decreased ADIPOQ Levels and GPDH Activity
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Figure 2.14: Control iMSCs Induced in the Presence of Carbenoxolone Formed Lipid
Droplets, but Exhibited Decreased ADIPOQ levels and GPDH. Control iMSCs induced in
the presence of carbenoxolone formed lipid droplets, but exhibited decreased ADIPOQ
mRNA levels, and GPDH activity. iMSCs were induced to differentiate in the presence or
absence of 1 mM probenecid or 50 μM of carbenoxolone. Lipid droplets were detected in
all of the induced cells, regardless of the drug treatment. Representative images of N=3.
Scale bar = 20 μm (A). There was no significant difference in the mRNA levels of CEBPα
(B) or LPL (C) between all of the induced cells, regardless of treatment. However, induced
iMSCs cultured with carbenoxolone had significantly lower ADIPOQ mRNA levels
compared to control cells (C). Induced cells cultured with either probenecid or
carbenoxolone had significantly lower levels of GPDH activity than control cells. (D)
GPDH Data is shown in mUnits/mg protein (mU/mg), where one unit is defined as the
GPDH activity necessary to oxidize one μmol of NADH per min. All data shown are the
mean of three independent trials performed in triplicate ± SEM. *, p<0.05; **, p<0.01
(Two-way ANOVA with post-hoc Tukey’s test). (E) Table showing the body mass index
(BMI), age of each donor and tissue origin
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ASCs actively form lipid droplets when induced to differentiate, this process was
dramatically inhibited when the cells were induced to differentiate in the presence of
carbenoxolone (Figure 2.15A). There was no significant difference in CEBPα (Figure
2.15B) and LPL (Figure 2.15C) mRNA levels between the induced untreated and treated
ASCs; however, induced carbenoxolone treated ASCs appeared to have much lower levels
of LPL mRNA compared to the other induced cell groups. In addition, induced
carbenoxolone treated ASCs has significantly lower levels ADIPOQ mRNA when
compared to the induced untreated ASCs (p<0.05) and the trend indicates that induced
carbenoxolone treated ASCs have lower ADIPOQ mRNA levels than induced probenecid
treated ASCs (Figure 2.15D). Finally, induced probenecid-treated ASCs had significantly
higher levels of GPDH activity compared to non-induced probenecid-treated ASCs
(p<0.05), which was not observed when cells were treated with carbenoxolone (Figure
2.15E). Overall, the trend indicates that induced carbenoxolone treated ASCs had lower
levels of adipocyte markets, indicating that carbenoxolone inhibited adipogenesis in ASCs.
To further assess that carbenoxolone inhibits adipogenesis, we measured the protein levels
of PPARγ, a key adipogenesis regulator, via immunoblotting (Rosen & MacDougald,
2006). PPARy has two isoforms, PPARγ1 and PPARγ2, where PPARγ1 (50 kDa) is found
in multiple tissue types while PPARγ2 (57 kDa) upregulation is a biomarker of cells
undergoing adipogenesis (Fajas et al., 1997; Ren et al., 2002). The trend indicated that
induced carbenoxolone-treated ASCs had lower levels of PPARγ2 compared to the induced
untreated and probenecid-treated ASCs (Figure 2.16C). PANX1 protein levels were also
analyzed to confirm that probenecid and carbenoxolone were not affecting PANX1
expression in the ASCs. As expected, there was no significant difference in PANX1 (Gly0,
Gly1 and Gly2 combined) protein levels between the experimental groups (Figure 2.16D).
We did not anticipate any changes in PANX1 protein levels in ASCs between the untreated,
probenecid, and carbenoxolone conditions, since the drugs are thought to only inhibit
channel function (Pinder et al., 1976; Silverman et al., 2009) and thus were not expected
to affect protein levels.
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Figure 2.15: Carbenoxolone Inhibits Adipogenesis in ASCs

84

Figure 2.15: Carbenoxolone Inhibits Adipogenesis in ASCs. ASCs were induced to
differentiate for seven days either untreated or treated with probenecid (Prob) or
carbenoxolone (CBX). (A) Lipid droplets were detected in the induced control and
probenecid ASCs; however, no lipid droplets were found in the induced carbenoxolone
ASCs. Representative brightfield images of N=4 n=3. Scale bar = 200 μm. (B-D) There
was no significant difference in adipogenic mRNA markers between induced ASCs,
regardless of drug treatment; however, the trend indicates that carbenoxolone induced
ASCs have lower levels of LPL mRNA compared to the control and probenecid induced
ASCs. The carbenoxolone induced ASCs had significantly lower levels of ADIPOQ
mRNA compared to control induced ASCs. Data shown are the mean of three independent
trials run in triplicate ± SEM. *, p<0.05 (Two-way ANOVA with post-hoc Tukey’s test).
(E) There was no significant difference in the GPDH activity among the induced cells. The
trend indicated that induced ASCs cultured with carbenoxolone had lower levels of GPDH
activity. Induced cells cultured in probenecid had significantly higher GPDH activity
compared to non-induced probenecid ASCs (p<0.05). (F) Table showing the body mass
index (BMI), age of each donor and tissue origin.
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Figure 2.16: Carbenoxolone Inhibits ASC Adipogenesis, as Indicated by the Absence
of PPARγ2 Protein

86

Figure 2.16: Carbenoxolone Inhibits ASC Adipogenesis, as Indicated by the Absence of
PPARγ2 Protein. ASCs were induced to differentiate for seven days in the absence or
presence of either probenecid (Prob.) or carbenoxolone (CBX). (A) Representative
immunoblot denoting PPARγ2 protein levels in ASCs from donor 1. Wild type AD293
cells and PANX1-ablated AD293 cells were used as negative controls. (B) Representative
immunoblot denoting PANX1 protein levels. Wild type AD293 cells and cells engineered
to overexpress human PANX1 were used as a positive control, while PANX1-ablated
AD293 cells were used as negative controls. There was no significant difference in either
the PPARγ2 (C) or PANX1 (D) protein levels between the experimental groups. Data
shown are the average protein levels of four independent trials ± SEM. (Two-way ANOVA
with post-hoc Tukey’s test). (E) Table showing the body mass index (BMI), age of each
donor and tissue origin.
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Since carbenoxolone is also capable of inhibiting gap junctional intercellular
communication (Pinder et al., 1976) in addition to PANX1 channel function, it is possible
that carbenoxolone was inhibiting connexin function in ASCs. Since Cx43 is known to be
expressed in adipocytes and pre-adipocytes (Yeganeh et al., 2012), we used
immunoblotting to determine if ASCs express Cx43 and whether it was expressed in ASCs
induced to differentiate. Immunoblotting indicated that Cx43 was expressed in control and
induced ASCs in the presence and absence of probenecid or carbenoxolone (Figure 2.17).
This study suggests that carbenoxolone may be acting to impair adipogenesis via its action
on Cx43 channels as opposed to its role in inhibiting PANX1 channels.
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Figure 2.17 Representative Immunoblotting Demonstrating the Presence of Connexin
43 in ASCs
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Figure 2.17: Representative Immunoblotting Demonstrating the Presence of Connexin 43
in ASCs. Representative immunoblots denoting the presence of connexin 43 (Cx43) and its
three phosphorylation states (P0, P1 and P2) in ASCs during adipogenesis. ASCs were
induced to differentiate over a period of seven days in the absence of presence of either
probenecid (Prob.) or carbenoxolone (CBX). Wild type AD293 were used as a positive
control. ASCs from donor 2 (Body Mass Index: 41.2; Age: 61; Tissue origin: Abdominal)
were used. N=1.
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2.4

Discussion

Pannexin 1 channels participate in paracrine signaling to communicate with neighboring
cells through the release of molecules into the extracellular space (Che et al., 2014). In fact,
pannexin 1 channels are responsible for releasing nucleotides, or ‘find me’ signals, to
recruit monocytes to apoptotic cells (Chekeni et al., 2010). MSCs are also well documented
for using paracrine signaling to release growth factors and cytokines, to adjacent cells to
prevent apoptosis as well as promote proliferation during tissue regeneration (Squillaro et
al., 2016a). Pannexin 1 has been reported to both promote skeletal myoblast differentiation
as well as dysregulate keratinocyte differentiation, signifying that the role of pannexin 1
during differentiation depends on the cell type (Celetti et al., 2010; Langlois et al., 2014).
Relevant to the current study, paracrine signaling has been reported to play a defining role
in regulating adipocyte differentiation within adipose tissue depots (Meissburger et al.,
2016). However, it is unclear whether PANX1 plays a role in paracrine signaling during
adipocyte differentiation in humans. A previous study demonstrated that Panx1-KO mice
had increased GPDH activity, lipid droplet formation, and adipocyte size, while also
exhibiting a reduced number of adipocytes, thus indicating that Panx1 inhibits adipogenesis
in mice (Lee et al., 2018). To determine if this finding also applies in the human context,
the role of PANX1 was studied when human iMSCs and ASCs were subjected to
adipogenesis under conditions where PANX1 function or levels were altered. In brief, the
pharmacological inhibition of PANX1 channels with carbenoxolone hindered adipogenesis
in both iMSCs and ASCs; however, PANX1-blocker probenecid was only able to hinder
adipogenesis in the iMSCs, but not the ASCs. Furthermore, PANX1 ablation did not affect
either iPSC differentiation into bona fide iMSCs, nor further differentiation along the
adipogenic lineage.
For both the iMSCs and ASCs, PANX1 mRNA levels increased during adipogenesis, but
this increase was not observed at the protein levels. The reason why the increase in PANX1
mRNA was not reflected by a parallel increase in the protein is not clear, but it may reflect
that the mRNA levels were unstable and subject to degradation prior to translation. Also,
it is noteworthy that PANX1 has a long half-life, thus avoiding the need for active synthesis
of new protein to maintain a high level of PANX1 function (Bhalla-Gehi et al., 2010).
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Supporting this notion, it has been shown that proteins with slower degradation rates have
a weaker correlation with their corresponding mRNA levels (Raj et al., 2006), which may
explain the discrepancy between the PANX1 mRNA and protein levels in MSCs during
adipogenesis.
Cell surface PANX1 has been consistently reported as an ATP release channel, so if
PANX1 plays a role in adipogenesis, it is likely to do so by its channel function and release
of critical signaling molecules (Penuela et al., 2007; Chekeni et al., 2010; Vandenbeuch et
al., 2015). A common approach used to study PANX1 function during differentiation is to
use pharmacological agents to inhibit its channel function (Silverman et al., 2009; Langlois
et al., 2014; Bhaskaracharya et al., 2014). Since a specific PANX1 inhibitor has yet to be
identified, carbenoxolone and probenecid have been used as the “best available” inhibitors
to block PANX1 channel function (Bruzzone et al., 2005; Locovei et al., 2006; Silverman
et al., 2008). Carbenoxolone is also a potent inhibitor of connexin channels and probenecid
is clinically used to block organic anion channels (Sagar & Larson, 2006; Silverman et al.,
2008) yet both drugs are potent at blocking pannexin 1 channels.
Drug-treated iMSCs were not able to differentiate along the adipogenic lineage, in contrast
to untreated iMSCs, prompting us to propose that PANX1 channel function is involved in
human adipogenesis. To assess the effects of pharmacologically inhibiting PANX1
function during adipogenesis using a second source of MSCs, we blocked PANX1 function
in ASCs (MSCs isolated from adipose tissue). The ASCs treated with carbenoxolone did
not differentiate; however, the probenecid-treated ASCs continued to differentiate similar
to untreated ASCs. Taken together, carbenoxolone consistently inhibited adipogenesis
from both stem cell sources, whereas probenecid had varying effects depending on the
MSC origin. One possibility that may explain the different findings is the fact that
carbenoxolone is a potent inhibitor of Cx43 gap junction channels that are found in MSCs
(Sagar & Larson, 2006; Wang et al., 2010). Since Cx43 plays a role in osteoblast
differentiation and skeletal myogenesis in vitro (Araya et al., 2005; Lin et al., 2018), there
is a possibility that Cx43 plays a critical role in adipogenesis. Besides PANX1 and
connexins, carbenoxolone has been reported to inhibit other proteins such as 11βhydroxysteroid dehydrogenase type 1 (HSD11B1), which facilitates adipogenesis through
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interaction with glucocorticoids (a core component in adipogenesis mediums) (Dhanesha
et al., 2012; Sano et al., 2012; Ghaben & Scherer, 2019). It is also notable that mice on a
HFD treated with carbenoxolone had reduced adipocyte size, a decrease in adipocyte
markers, and an overall reduction in fat accumulation (Sano et al., 2012). In another study,
HSD11B1-knockout mice were protected against obesity and hyperglycemia (Kotelevtsev
et al., 1997). Thus, it is possible that carbenoxolone inhibited HSD11B1 in both the iMSCs
and the ASCs, effectively inhibiting adipogenesis as indicated by the absence of adipocyte
markers. Due to the non-specificity of carbenoxolone, it was difficult to determine whether
PANX1 channel inhibition halted adipogenesis, hence we used another PANX1-blocker
drug, probenecid, and also generated PANX1-ablated MSCs to study PANX1 during
adipogenesis.
Our study found that adipogenesis was inhibited in probenecid treated iMSCs, but not the
ASCs. The discrepancy between the differentiation capacity of probenecid-treated iMSCs
and ASCs was remarkable, suggesting that MSCs from different sources may activate
different mechanisms to guide their cell fate. Probenecid in human preadipocytes has been
shown to promote adipogenesis by activating the non-selective cation channel transient
receptor potential vanilloid 2 (TRPV2), which regulates intracellular calcium signaling
(Che et al., 2014). Thus, differences in probenecid treatment between the iMSCs and ASCs
may be possibly explained by the fact that MSCs from different sources have distinct
proteomes. A comparison of proteome expression between BM-MSCs and ASCs revealed
that 23% of the proteins were uniquely expressed in either the BM-MSCs or the ASCs, and
a further 18% of the proteins were expressed at different levels between the BM-MSCs and
ASCs (Noël et al., 2008). In keeping with this notion, we found that ASCs had a
significantly higher level of PANX1 protein compared to iMSCS in both the induced and
non-induced conditions. It is possible that probenecid is inhibiting PANX1 and/or altering
the function of other proteins which are differentially expressed between the two MSC
types, resulting in different responses to probenecid during adipogenesis.
While the pharmacological blocking of PANX1 channels was used to show that PANX1
function is dispensable for adipogenesis, we wanted to further assess if other PANX1
properties might exist that are critical in adipogenesis. In addition to being a large pore
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channel, PANX1 can also interact with other binding partners to facilitate cell signaling
(Silverman et al., 2008; Penuela et al., 2013). Therefore, a PANX1-ablated iPSC cell
population was engineered to determine if eliminating PANX1 would affect adipogenesis.
PANX1-ablated iMSCs were able to differentiate into iMSCs, and further differentiate
along the adipogenic lineage, indicating that the PANX1 protein is not necessary for human
adipogenesis in vitro. Moreover, no significant differences were observed in any of the
adipocyte markers between the PANX1-ablated and control iMSCs. Thus, neither PANX1
channel function nor the PANX1 protein itself affect adipogenesis.
As revealed in our studies, iMSCs and ASCs exhibited distinct differentiation potential that
may engage distinct mechanisms, highlighting the uniqueness of iMSCs and ASCs. Based
on the increased expression of adipocyte markers and lipid droplet formations, iMSCs were
able to initiate adipogenesis, but were unable to reach later stages of adipogenesis after
fourteen days of differentiation. On the other hand, the ASCs were able to proceed further
along the adipogenic lineage and achieve later stages of adipogenesis in a shorter period of
time (7 days), suggesting that the ASCs have a greater adipogenic potential compared to
the iMSCs. This is in line with previous studies that have demonstrated that MSCs from
different tissue origins possess unique differentiation capacities, where ASCs have a higher
capacity to differentiate into adipocytes in comparison to BM-MSCs (Li et al., 2015;
Mohamed-Ahmed et al., 2018). Moreover, recent studies have shown that iMSCs have a
lower adipocyte differentiation capacity compared to BM-MSCs, which further supports
our findings that the iMSCs have an inferior adipogenic potential in comparison to ASCs
(Hynes et al., 2014; Kang et al., 2015). Differences in adipogenic induction media may
also contribute to the difference between the adipogenic potential of the human iMSC and
ASCs in our study. The iMSCs were induced to differentiate using the StemPro
Adipogenesis Differentiation Kit while the ASCs were induced using a previously
published media by Flynn (2010). Since the StemPro Adipogenesis Differentiation Kit is
proprietary, it is impossible to identify if differences in the adipogenic cocktails may also
account for the differences in adipogenesis. However, one difference that can be identified
is that ASC media is prepared fresh in contrast to the commercial kit where the stability of
the active components may be a factor which, along with different media compositions,
may have an impact on the efficiency of stem cell differentiation.
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Our finding that PANX1 was dispensable in human MSCs differentiation was somewhat
surprising since Panx1-knockout mice have been shown to have enhanced adipogenesis
(Lee et al., 2018). In terms of cellular differences, murine and human ASCs have different
protein expression profiles. For example, it is known that catecholamine-lipolysis occurs
through the activation of β-adrenergic receptor (β-AR) subtypes, β1, β2 and β3 (Chusyd et
al., 2016). While, humans and mice both express β1 and β2, but only mice express β3-ARs
(Chusyd et al., 2016). Therefore, β3-AR agonists can initiate lipolysis in mice, but this
phenomenon is not observed in humans in vitro or in vivo (Tavemier et al., 1996; Weyer
et al., 1998). In another example, humans express α2-adrenergic receptors, which are also
activated by catecholamines to inhibit lipolysis (Chusyd et al., 2016). Mice do not express
α2-adrenergic receptors; therefore, catecholamines may have different effects on
adipogenic lipolysis depending on the species (Langin, 2006). With regards to
adipogenesis, LIM domain only 3 (LMO3) is a transcription cofactor that acts as a
proadipogenic regulator in human ASCs and adipose tissue, but is absent in murine
adipogenesis (Lindroos et al., 2013). Glucocorticoids, a core component of adipogenic
media, activates LMO3 to interact with HSD11B1 to facilitate adipogenesis. Furthermore,
inhibition of LMO3 in human ASCs resulted in decreased adipogenesis and lipid
accumulation. However, glucocorticoid treatment in murine ASCs had no effect on LMO3
expression. Although glucocorticoids have been reported to induce adipogenesis in both
mice and humans, there are differences in protein expression and regulatory mechanisms
between the two species that may result in differences in adipogenesis.
As noted earlier, another possible explanation for the differences between the murine ASCs
and the human iMSC results reported here is the source of stem cells being compared as
they have been reported to exhibit distinct adipogenic potentials (Kang et al., 2015;
Mohamed-Ahmed et al., 2018). Also Lee et al. (2018), studied adipogenesis in male
murine ASCs, while we utilized female human ASCs raising the possibility that sex may
play a role. In one study, the quantity of ASCs harvested from female mice was 2.9 times
greater than that of male mice, and in another study, women were reported to have larger
subcutaneous adipose tissue than when compared to men (Björntorp, 1991; Chusyd et al.,
2016). In addition to differences between MSC source, species, and sex, we recognize that
examining adipogenesis in vitro does not completely recapitulate the microenvironments
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that occur in vivo. For example, the loss of membrane-bound matrix metalloproteinase-14,
which was found to inhibit adipogenesis in vivo, had no effect on adipogenesis in vitro 2
dimensional cultures (Chun et al., 2006). Thus, caution needs to be exercised as PANX1
may have a role in human adipogenesis which might only be revealed in vivo.
Although PANX1 is ubiquitously found throughout the human body (Baranova et al.,
2004), the specific role of this channel forming protein is only beginning to be understood.
While Panx1 was shown to be negative regulator of adipogenesis in mice, here we used
two sources of human mesenchymal stem cells to show that it is dispensable for in vitro
adipogenesis, even though PANX1 is found in these stem cell populations. As clinical
approaches are designed to deal with the obesity epidemic, assuming that our findings
translate to the in vivo setting, we propose that PANX1 is not a key regulatory of
adipogenesis. Finally, our results using a pharmacological inhibitor of gap junction
channels suggests that connexins may play a critical role in human adipogenesis, but
further investigations are needed to confirm its possible role.
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Chapter 3

3

General Discussion

Adipose tissue is the largest endocrine organ in the body, and serves multiple functions
such as storing energy, maintaining metabolic homeostasis, regulating inflammation, and
facilitating wound healing (Gesta et al., 2007; Ghaben & Scherer, 2019). Adipogenesis has
been associated with pathologies such as obesity and metabolic syndrome, where
dysfunctional adipogenesis can result in severe health risks (Spiegelman & Flier, 1996;
Gesta et al., 2007). On the other hand, adipogenesis has been linked to tissue regeneration
and vascularization, where mesenchymal stem cells (MSCs) and adipocytes have been used
to treat acute burns and chronic non-healing ulcers (Marino et al., 2013; Hassan et al.,
2014; Na et al., 2017). Understanding how adipogenesis occurs and what factors influence
this process can prove to be useful in treating adipocyte pathologies and improving adipose
tissue-based treatments. Based on a previous study, where pannexin 1 was found to inhibit
adipogenesis in mice (Lee et al., 2018), pannexin 1 emerged as a potential target in the
fight against obesity. In a novel approach, our study investigated the role of human
pannexin 1 (PANX1) during in vitro adipogenesis using adipose derived stem cells (ASCs)
and induced MSCs (iMSCs) derived from induced pluripotent stem cells (iPSCs). Here,
our findings will be integrated with what is currently understood in the field of pannexins,
adipogenesis, and MSCs, as well as address potential avenues for future research.
3.1

Possible Role of PANX1 in Late Stages of Adipogenesis

Although PANX1 appears to play a role in adipocyte functions such as insulin sensitivity
and inflammation, our findings indicate that PANX1 is not necessary for human adipocyte
differentiation in vitro (Silverman et al., 2009; Adamson et al., 2015). Adipogenesis can
be broken down into two stages: the commitment stage, where MSCs become
preadipocytes, and the differentiation stage, where the preadipocyte differentiate into
mature adipocytes (Ghaben & Scherer, 2019). The transition from preadipocyte into mature
adipocytes can be further divided into four stages: growth arrest, colonial expansion, early
differentiation, and terminal differentiation (Gesta et al., 2007). After growth arrest,

105

extracellular ATP has no effect as the cells undergo adipogenesis (Omatsu-Kanbe et al.,
2006). Therefore PANX1's function as an ATP release channel is not predicted to have
much impact during early differentiation. It is possible that PANX1 is necessary for mature
adipocyte function, and that the MSCs used in this study did not reach a point along the
adipogenic lineage where PANX1 was necessary for adipocyte function.
3.2

MSCs from Different Sources are Not Identical

Due to their therapeutic potential, MSCs have proven to be a promising tool in regenerative
medicine and have been the focal point of over 500 clinical trials (clincialtrial.gov;
Squillaro et al., 2016). MSCs were originally discovered in bone marrow, and hence the
properties of bone marrow derived MSCs (BM-MSCs) have been studied extensively
(Friedenstein et al., 1968; Strioga et al., 2012). Since then, MSCs have been collected from
a variety of sources, including adipose tissue and iPSC sources (Wei et al., 2013; Kang et
al., 2015). Each type of MSC has its advantages and disadvantages. BM-MSCs are isolated
from bone marrow through an invasive surgery with high risk of infection (MohamedAhmed et al., 2018). BM-MSCs prefer to differentiate towards osteogenic and
chondrogenic lineages, and are less inclined to undergo adipogenesis (Mohamed-Ahmed
et al., 2018). ASCs, on the other hand, have a greater preference for adipogenic lineages,
rather than osteogenesis or chondrogenesis, making them ideal candidates for adiposerelated surgeries (Mohamed-Ahmed et al., 2018). Furthermore, ASCs are preferred over
BM-MSCs, since adipose tissue is routinely collected during fat reduction surgeries (Kim
& Heo, 2014). There is also a higher yield of ASCs per gram of fat when compared to bone
marrow tissue (Hass et al., 2011). To put this into perspective, only 0.001 to 0.01% of the
total cells in a sample of bone marrow are MSCs, where as in an equivalent amount of
adipose tissue, about 5% of the cells are MSCs (Hass et al., 2011). Finally, iMSCs are ideal
because iPSCs are capable of infinite renewal, and can offer an unlimited supply of MSCs
(Hafner & Dani, 2014; Kang et al., 2015). However, iPSCs are genetically reprogrammed
somatic stem cells, and these genetic modification may have an impact on the MSC
characteristics (Hynes et al., 2014; Kang et al., 2015). Previous studies have shown that
iMSCs share a similar potential for osteogenesis and chondrogenesis as BM-MSCs;
however, iMSCs have a lower adipogenic potential when compared to BM-MSCs (Kang
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et al., 2015). A possible explanation for the variabilities between the MSCs from different
tissue sources is that the tissue-specific cellular microenvironments may have a profound
and lingering influence on the cells’ adipogenic characteristics after isolation (Lowe et al.,
2011). In the future, detailed characterization of MSCs from different sources are necessary
to distinguish the effects of tissue origin on MSC potential.
3.3

Limitations and Future Directions

Our study is the first to focus on the role of PANX1 in human adipogenesis in vitro. Here,
we demonstrated that PANX1 was not required for differentiation from iPSCs into iMSCs,
nor further differentiation along the adipogenic lineage. Furthermore, the differential
response to pharmacological inhibitors indicate that iMSCs and ASCs should be treated as
somewhat different cell types. In short, our findings suggest that PANX1 is not necessary
for human adipogenesis in vitro.
Within our study, we faced limitations such as studying only one source of iMSCs, only
utilizing female ASCs from patients with a high body mass index (BMI), high patient to
patient variability, and the lack of drugs that can specifically block PANX1. Because of
these limitations, open questions remain about the role of PANX1 in human adipogenesis.
One of these questions is whether our key findings apply to both male and female cohorts
of all ethnic background and ages, as one of the limitations in our study was that all the
cells were isolated from female donors. In fact, the cells from the iMSC studies were
derived from a single female donor. For the ASC studies, the adipose tissue was donated
by overweight or obese females, all with a BMI >25, who were all over the age of 23
(World Health Organization, 2000). Previous studies have reported that age, sex, and BMI
can have an impact on adipogenesis (van Harmelen et al., 2003; Ogawa et al., 2004;
Karastergiou & Fried, 2017). Furthermore, because of the patients’ age, our findings reflect
adult adipogenesis, and so we cannot exclude the possibility that PANX1 plays a role
during early childhood adipocyte development. To confirm the generality of our findings,
additional samples are required from patients with a broader BMI and age range, as well
as from both sexes.
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Carbenoxolone and probenecid were used to block PANX1 channel function; however,
these drugs are non-specific. Carbenoxolone is a potent inhibitor of gap junctions, and
probenecid is clinically used to inhibit organic anion transporters (Pinder et al., 1976;
Silverman et al., 2008, 2009). It is unfortunate that better drugs are not available to
specifically block PANX1 channels with no off-target effects. Although previous studies
have shown that 1 mM probenecid inhibits human PANX1 channels in skeletal myoblast
cells and other cell types (Silverman et al., 2008; Langlois et al., 2014), we have no
definitive evidence that 1 mM probenecid and 50 μM carbenoxolone inhibits PANX1 in
iMSCs and ASCs. Further studies using ATP release assays (Shao et al., 2016) and
electrophysiological assessment of PANX1 channel activity (Locovei et al., 2006;
Silverman et al., 2008) should be performed to confirm that PANX1 channels in iMSCs
and ASCs are indeed being inhibited by probenecid and carbenoxolone.
Carbenoxolone was able to inhibit adipogenesis in both the iMSCs and ASCs. Since it is a
non-specific drug, there is a possibility that carbenoxolone inhibited adipogenesis by
blocking other proteins (Pinder et al., 1976; Sano et al., 2012). Carbenoxolone is primarily
known as a potent gap junction inhibitor, therefore, it is worth investigating whether
carbenoxolone is inhibiting adipogenesis by blocking connexin channels. Since connexin
43 (Cx43) is the most abundant connexin expressed in adipose tissue (Burke et al., 2014;
Zhu et al., 2016), we can begin with the assumption that carbenoxolone is inhibiting Cx43.
Therefore, Cx43-ablated MSCs can be generated and induced to differentiate. If the cells
are able to reach later stages of adipogenesis, then carbenoxolone is inhibiting adipogenesis
by blocking a protein other than Cx43. It is noteworthy to mention that carbenoxolone
inhibits hydroxysteroid 11-beta dehydrogenase 1 (HSD11b1), which can be activated by
glucocorticoids to initiate adipogenesis, and so it is another promising target to probe about
the mechanism behind carbenoxolone inhibiting adipogenesis in MSCs (Sano et al., 2012).
Elucidating the mechanisms that carbenoxolone uses to repress adipogenesis can help to
understand what factors are necessary for adipocyte differentiation in humans.
On the other hand, probenecid was only able to inhibit later stages of adipogenesis in the
iMSCs, but had no effect on adipogenesis in the ASCs. This was surprising since we
believed that probenecid would have the same effect on MSCs, regardless of origin. This
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leads to another open question, what is the difference between iMSCs and ASCs that can
explain the different responses to probenecid during adipogenesis? It is possible that the
different origins and/or genetic reprogramming of iPSCs may influence the proteomes of
iMSCs and ASCs, as it has been reported that the iPSCs may retain epigenetic memory
from their somatic cell type, which causes differential gene expression and differentiation
capacity (Polo et al., 2010). To further study the effects of origin on differentiation
capacity, different types of stromal cells, including ASCs, can be reprogrammed into
iPSCs, and then further into iMSCs. These iMSC clones, as well as unedited ASCs, can
then be induced along the adipogenic lineage, and analyzed to determine if the proteomics
and adipogenic capacity differ between these iMSC clones and unedited ASCs. If so, we
can conclude whether cell origin or iPSC genetic reprogramming is responsible for the
differences in protein levels.
In terms of ASC differentiation, one of the differences between our study and the study by
Lee et al. (2018) is the length of adipogenic induction. In the study by Lee et al. (2018),
after fourteen days of mouse adipogenic induction, murine pannexin 1 (Panx1) ablated
ASCs had increased lipid content, glycerol-3-phosphate dehydrogenase (GPDH) activity,
and secretion of adiponectin and leptin, indicating that Panx1-ablated ASCs had increased
adipocyte functionality when compared to the wild type ASCs. On the other hand, our
study induced human ASCs toward the adipogenic lineage for only seven days, and there
were no significant differences in adipogenic markers between the drug-treated ASCs and
the untreated ASCs. Although the drugs may be the reason why there was no significant
difference, another possible factor is the shorter differentiation period, which may not have
offered an opportunity for PANX1 to play its role in adipogenesis. The reason why we did
not induce the human cells for fourteen days is because lipid droplet formation causes the
ASCs to lift due to the change in cell density, hence these cells become difficult to study.
If the human ASCs were effectively cultured for a longer period, it is possible that the
differences in adipogenic markers between the drug-treated and control ASCs would have
become significant.
It is also important to note that three dimensional (3D) cultures have been developed to
study adipogenesis in a more physiologically relevant model (Emont et al., 2015). For
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instance, the loss of matrix metallopeptidase 14 inhibited adipogenesis in vivo, and while
this finding has been replicated with 3D cultures, it was not observed when the experiment
was performed using two dimensional (2D) cultures (Chun et al., 2006; Lowe et al., 2011).
Therefore, it is possible that PANX1 plays a role in adipogenesis in vivo, and that this
would only be observed in vitro by using 3D cultures. Ideally, using a 3D culture will help
to give us a better idea of how PANX1 influences adipogenesis in vivo. However, there are
many reported challenges in designing 3D cultures: constructing proper distribution
systems for oxygen, carbon dioxide, nutrients, and waste throughout the culture, the tissuetissue interfaces, as well as controlling for other microenvironmental factors which are
observed in vivo (Duval et al., 2017). On top of these challenges, a standard 3D culturing
system has yet to be implemented to maintain consistency within the field (Duval et al.,
2017). Although the 3D cultures offer a more physiologically relevant model, it requires
more time and funding to perfect these systems.
Going forward it might be useful to use clustered regularly interspaced short palindromic
repeat associated caspase 9 (CRISPR/Cas9) approaches to develop PANX1-ablated ASCs
and determine whether they can differentiate along the adipogenic lineage. However, this
would be challenging due to the fact that ASCs are viable as stem cells for only a limited
number of passages before they begin to senesce (Yang et al., 2018). Furthermore, it is
clinically recommended to use MSCs between passage 3 to 5, therefore it is ideal to study
ASCs at passage 5 or lower (Jiang et al., 2017). Alternatively, one might consider using
short hairpin RNA approaches to knockdown PANX1 and assess adipogenesis (Locovei et
al., 2006). This would generate a second source of PANX1-attenuated MSCs to study
adipogenesis, which would provide another avenue to validate our findings.
From this study, we found that, although iMSCs and ASCs meet the minimum
requirements to be classified as MSCs, these cells have distinct properties, exemplified in
the different responses to probenecid during adipogenesis. In addition, PANX1 does not
appear to be necessary for iPSC differentiation into iMSCs, nor further differentiation
along the adipogenic lineage. Overall, future studies are required to elucidate the role of
PANX1 during adipogenesis in the human context.
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AUP Number: 2019-009
PI Name: Laird, Dale W
AUP Title: The role of connexin and pannexin channels in health and disease
Approval Date: 05/01/2019
Official Notice of Animal Care Committee (ACC) Approval:
Your new Animal Use Protocol (AUP) 2019-009:1: entitled " The role of connexin and
pannexin channels in health and disease has been APPROVED by the Animal Care
Committee of the University Council on Animal Care. This approval, although valid for
up to four years, is subject to annual Protocol Renewal.
Prior to commencing animal work, please review your AUP with your research team to
ensure full understanding by everyone listed within this AUP.
As per your declaration within this approved AUP, you are obligated to ensure that:
1. Animals used in this research project will be cared for in alignment with:
a. Western's Senate MAPPs 7.12, 7.10, and 7.15
http://www.uwo.ca/univsec/policies_procedures/research.html
b. University Council on Animal Care Policies and related Animal Care
Committee procedures
http://uwo.ca/research/services/animalethics/animal_care_and_use_policies.htm
2. As per UCAC's Animal Use Protocols Policy,
a. this AUP accurately represents intended animal use;
b. external approvals associated with this AUP, including permits and
scientific/departmental peer approvals, are complete and accurate;
c. any divergence from this AUP will not be undertaken until the related
Protocol Modification is approved by the ACC; and
d. AUP form submissions - Annual Protocol Renewals and Full AUP
Renewals - will be submitted and attended to within timeframes outlined by
the ACC.
e. http://uwo.ca/research/services/animalethics/animal_use_protocols.html
3. As per MAPP 7.10 all individuals listed within this AUP as having any hands-on
animal contact will
a. be made familiar with and have direct access to this AUP;
b. complete all required CCAC mandatory training (training@uwo.ca); and
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c. be overseen by me to ensure appropriate care and use of animals.
4. As per MAPP 7.15,
a. Practice will align with approved AUP elements;
b. Unrestricted access to all animal areas will be given to ACVS Veterinarians
and ACC Leaders;
c. UCAC policies and related ACC procedures will be followed, including but
not limited to:
i. Research Animal Procurement
ii. Animal Care and Use Records
iii. Sick Animal Response
iv. Continuing Care Visits
5. As per institutional OH&S policies, all individuals listed within this AUP who will
be using or potentially exposed to hazardous materials will have completed in
advance the appropriate institutional OH&S training, facility-level training, and
reviewed
related
(M)SDS
Sheets,
http://www.uwo.ca/hr/learning/required/index.html
Submitted by: Copeman, Laura
on behalf of the Animal Care Committee
University Council on Animal Care

Dr. Timothy Regnault,
Animal Care Committee Chair

The University of Western Ontario
Animal Care Committee / University Council on Animal Care
London, Ontario Canada N6A 5C1
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